




PATHOLOGY OF FELINE CHRONIC KIDNEY DISEASE:  HISTOMORPHOLOGIC  
 
CHARACTERIZATION OF RENAL AND GASTRIC LESIONS; AND AN INVESTIGATION   
 








Shannon M. McLeland 
 






In partial fulfillment of the requirements 
 
For the Degree of Doctor of Philosophy 
 
Colorado State University 
 










 Advisor:  Steve Dow  
 Co-Advisor:  Michael Lappin 
 
Robert Callan 
 Colleen Duncan 
 Jessica Quimby
Copyright by Shannon M. McLeland 2015 





PATHOLOGY OF FELINE CHRONIC KIDNEY DISEASE:  HISTOMORPHOLOGIC  
 
CHARACTERIZATION OF RENAL AND GASTRIC LESIONS; AND AN INVESTIGATION   
 
INTO THE EXPRESSION OF RENAL α-ENOLASE 
 
 
Feline chronic kidney disease (CKD) is a common disease among older cats and is 
associated with high morbidity and decreased survival.  A definitive cause or potential factors 
that initiate this highly prevalent disease have been elusive.  The overall goal of this body of 
work was twofold; to better characterize, histopathologically, the renal and associated gastric 
manifestations of CKD, and secondly, explore the potential role of vaccinations and 
autoantibodies in cats with CKD. 
In the first study the presence and severity of both reversible and irreversible 
histopathologic lesions were evaluated in the kidneys of cats at each stage of CKD.  A total of 46 
cats with CKD were classified according to the International Renal Interest Society (IRIS) as: 
Stage I (3 cats), Stage II (16 cats), Stage III (14 cats), and Stage IV (13 cats).  Eleven young, 
non-azotemic and 10 geriatric, non-azotemic cats were included as controls.  The severity of 
tubular degeneration, interstitial inflammation, fibrosis, and glomerulosclerosis was significantly 
greater in later stages of CKD compared to early stages of disease. Proteinuria was associated 
with increased severity of tubular degeneration, inflammation, fibrosis, tubular epithelial single 
cell necrosis and decreased normal parenchyma. Presence of hyperplastic arteriolosclerosis, 
fibrointimal hyperplasia, or other vascular lesions was not found to be significantly different 
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between hypertensive and normotensive cats. Irreversible lesions such as interstitial fibrosis were 
more common and severe in later stages of CKD (Stage III and IV). 
Chronic kidney disease in cats is associated with gastrointestinal signs commonly 
attributed to uremic gastropathy. Symptomatic therapy is based on documented gastric lesions in 
other species.  The objective of this study was to determine the prevalence and characterize 
gastric lesions in cats with CKD.  Samples from a total of 37 CKD cats and 12 non-azotemic 
control cats were evaluated.  Characterized lesions were compared with serum creatinine 
concentrations, calcium-phosphorus product (CPP) and serum gastrin concentrations.  Gastric 
ulceration, hemorrhage, edema, and vascular injury, were not observed in cats with CKD. The 
most significant gastric lesions in CKD cats were fibrosis and mineralization. Sixteen CKD cats 
(43%) had evidence of gastric fibrosis of varying severity and 14 CKD cats (38%) had gastric 
mineralization. Cats with CKD were more likely to have gastric fibrosis and mineralization than 
non-azotemic controls (p=0.005 and p=0.021, respectively). Only cats with moderate and severe 
azotemia had gastric mineralization. CPP was correlated to disease severity; severely azotemic 
CKD cats had significantly greater CPP when compared to non-azotemic controls, and to mildly 
and moderately azotemic cats (p<0.05). Gastrin concentrations were significantly greater in CKD 
cats when compared to non-azotemic controls (p=0.003) but elevated concentrations were not 
associated with gastric ulceration. 
Vaccinations against feline viral rhinotracheitis, calicivirus, and panleukopenia (FVRCP) 
and vaccine cell lysates (CRFK) can induce autoantibodies that target α-enolase protein.  In 
addition, a subset of these cats with antibodies against CRFK lysates developed interstitial 
nephritis when hyperinoculated.  Alpha-enolase, a ubiquitous, glycolytic enzyme has been 
implicated as a self-antigen in various autoimmune diseases, some of which are associated with 
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active nephritis in human patients.  Plasma cell membrane expression of α-enolase has been 
identified as a target of autoantibodies. 
The focus of these dissertation chapters was threefold.  First, to determine if cats with 
CKD have anti-α-enolase antibodies and if levels of antibodies vary with severity of disease (i.e. 
IRIS stage) or FVRCP vaccine history.  Second, to characterize α-enolase expression in feline 
tissues and renal subcellular fractions in health and in feline CKD.  Third, to determine if 
antibodies in the sera from CKD cats are capable of targeting feline endogenous renal proteins.  
Twenty-nine CKD cats and healthy, unvaccinated control cats (n=8) were included.  CKD cats 
consisted of 9 Stage II cats, 8 Stage III cats, and 12 Stage IV cats. 
Cat with CKD, regardless of vaccine history, had significantly greater levels of α-enolase 
antibodies than controls (p<0.0001).  No difference in the levels of antibodies between vaccine 
groups or IRIS stage was found.  Alpha-enolase protein was differentially expressed in the 
kidneys of cats with CKD by immunohistochemistry. In healthy kidneys, α-enolase protein 
immunoreactivity was moderate in tubular epithelium but absent in glomeruli.  In contrast, α-
enolase expression was significantly decreased in tubules that were degenerative or atrophic in 
kidneys of CKD cats with significantly more expression in glomeruli relative to healthy controls.  
All but one CKD (n=28) cat had cytosolic α-enolase while membranous protein expression was 
less frequent (n=16).   However, membranous expression was more common in later stages of 
disease (i.e. Stage III and IV).  Immunoglobulin G from the sera of CKD and non-azotemic cats 
were shown to target recombinant α-enolase, as well as, cytosolic and membranous protein at 
approximately 52 kDa by immunoblot.  These data indicate that α-enolase antibodies are 
commonly found in sera of cats with CKD and are capable of binding endogenous renal proteins.  
Lastly, α-enolase protein is overexpressed in glomeruli with decreased expression in injured 
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renal tubules of cats with CKD.  Together this work indicates that anti-α-enolase antibodies are 
common in cat sera and that renal α-enolase protein is altered in both the cellular population 
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CHAPTER 1:  LITERATURE REVIEW 
 
 
The total production or output of a factory may fall for one of two reasons.  The team of 
workers may become slack or may not have enough to do, like the nephrons in heart 
failure; or the team may have been seriously depleted in numbers owing to illness, the 
few remaining workers actually putting in overtime in an unsuccessful attempt to 
compensate for the absence of their fellows.  The latter is the state of affairs in 
experimental renal failure, as our obliging rats have clearly demonstrated, and there is 
good reason to believe that it is the state of affairs also in chronic renal failure in the 
human subject.2  
 
 
1.1 Feline chronic kidney disease 
1.1.1 Prevalence of feline chronic kidney disease 
Chronic kidney disease (CKD) is associated with decreased survival and considerable morbidity 
in felines.5 Reports on prevalence vary but it is the consensus that aged cats are particularly 
affected.6-8  Within the general feline population prevalence of CKD is 1%-3%.9  According to 
the State of Health Report issued by Banfield Pet Hospitals 160 per 10,000 feline patients seen 
annually have kidney disease which has increased in incidence 15% since 2007.10  Lastly in a 
retrospective study of the co-prevalence of degenerative joint disease and CKD as many as 50% 
of study cats without and 68% of cats with  degenerative joint disease had CKD.6   
1.1.2 Pathology of feline chronic kidney disease 
Chronic kidney disease is characterized by a reduction of structural and functional components 
resulting in retention of metabolic waste products, decreased urinary concentrating ability, and 
variable electrolyte and acid-base imbalances.5, 7, 8 The most frequent morphologic diagnosis is 
chronic tubulointerstitial nephritis.7  Other infrequent primary renal diseases that will cause renal 
dysfunction include of lymphosarcoma, amyloidosis, chronic pyelonephritis, and polycystic 
kidney disease.7  CKD is progressive which in part is due to interstitial fibrosis--a common end 
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point that correlates with a decline of renal function.11-13  The tubulointerstitium in particular 
appears to be the focus of renal injury in feline CKD. In addition to interstitial fibrosis, 
mononuclear inflammation and tubular atrophy are typical morphologic changes in chronic 
tubulointerstitial renal disease.14, 15  In a histomorphologic study of felines in the United 
Kingdom interstitial fibrosis was the best histologic correlate to azotemia, hyperphosphatemia, 
and anemia in cats with CKD.12  Additionally, fibrosis scores correlated with interstitial 
inflammation and glomerular obsolescence.12  Primary glomerular lesions in cats with CKD are 
uncommon.7, 8, 12   
1.1.3 Renal fibrosis 
Renal fibrosis, or scarring, is the accumulation of extracellular matrix which irreversibly replaces 
normal tissue.11, 16  Interstitial fibroblasts, the culprit of fibroplasia, can be derived from resident 
fibroblasts, migration of pericytes, recruitment of mesenchymal cells from circulation, and 
transformation of tubular epithelial or endothelial cells.11  Production of extracellular matrix by 
fibroblasts is regulated by various growth factors, leukocyte interactions, and physiologic 
stimuli.16, 17  Transforming growth factor β (TGF-β) is an important renal pro-fibrotic mediator 
and is up-regulated in all mammalian chronic kidney diseases.16  Pro-fibrotic effects include 
induction of various cells to a myofibroblast phenotype, a key event in initiation and progression 
of fibrosis; stimulation of extracellular matrix (ECM) gene transcription, and activation of other 
pro-fibrotic cytokines.18-21 
The renin-angiotensin-aldosterone system (RAAS) is crucial for renal homeostasis and is 
up-regulated in CKD.16 The individual members of the RAAS system have direct pro-fibrotic 
effects.  Angiotensin, aldosterone and renin are capable of up-regulating TGF-β expression along 
with other pro-inflammatory and pro-fibrotic mediators.16  Expression of transglutaminase 2 
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(TG-2), an enzyme that stabilizes the extracellular matrix is associated with renal fibrosis in cats 
with CKD as well.22 
A few other factors that contribute to renal injury and fibrosis include proteinuria, 
interstitial inflammation, and hypoxia.  Protein can be directly toxic to tubular epithelial cells as 
well as contribute to epithelial to mesenchymal transition of tubular epithelial cells.16, 23, 24  
Inflammatory cells produce pro-fibrotic growth factors necessary for propagation of fibrosis.16 
Hypoxia promotes fibrogenesis by several mechanisms.  A few of these mechanisms include 
epithelial to mesenchymal transition, induction of pro-fibrotic mediators by fibroblasts, 
decreased matrix turnover and increased matrix production.25, 26 
In conclusion, there are numerous factors that contribute to renal fibrosis, a few which 
were discussed here.  Fibrosis is considered irreversible, is a common end point of renal injury, 
and is progressive.  The importance of understanding factors that contribute to initiation and 
propagation of fibrosis in the cat kidney could have preventative and therapeutic implications. 
1.1.4 Staging of feline chronic kidney disease 
The International Renal Interest Society was originally organized by veterinarians with an 
interest in nephrology at the 8th Annual Congress of the European Society of Veterinary Internal 
Medicine in Vienna, Austria in 1998.  It is supported by Novartis Animal Health that provides 
financial and organizational assistance.  The primary objective of this group was to establish a 
set of guidelines to aid the clinician in diagnosis and treatment of kidney disease in dogs and 
cats.  Stages are determined by two serial serum creatinine concentrations measured in a stable 
patient.  Stage I cats are not azotemic but at risk due to kidney abnormalities such as decreased 
urine specific gravity, renal proteinuria, or abnormal appearance on ultrasound or renal biopsy.  
Stage II cats have serum creatinine concentrations of 1.6-2.8 mg/dl, 2.8-5.0 mg/dl for Stage III, 
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and >5.0 mg/dl for Stage IV cats.  In addition, renal disease is sub-staged based on presence of 
proteinuria and hypertension which increases the risk of additional organ damage.27 
A recent study evaluating survival of CKD cats based on IRIS stage was reported.28  Overall 
median survival for cats with kidney disease was 771 days from the time of diagnosis and 
survival was significantly less with increasing stage.  For cats with serum creatinine 
concentrations of 2.3-2.8 mg/dl, which lies within the upper half of the defined Stage II by IRIS 
(i.e. Stage IIb), median survival was 1,511 days.  Stage III cats had a median survival of 778 
days while Stage IV cats median survival was only 103 days from the time of diagnosis.  
Clinicopathologic parameters were evaluated as risk factors for survival.  Age at the time of 
diagnosis, albumin, blood urea nitrogen (BUN), creatinine, calcium, bicarbonate, potassium, and 
hematocrit were not predictive of survival.  Hyperphosphatemia was the only variable identified 
as a risk factor.  For every unit increase in phosphorus the risk for death increased 11.8% in cats 
with CKD.28 These data and IRIS scoring for cats with kidney disease can aid the clinician in 
communicating potential risks and prognosis to pet owners.   
1.2 Uremic gastropathy 
1.2.1 The uremic syndrome 
Uremia, a clinical syndrome of chronic kidney disease, is due to retention of toxic metabolic 
byproducts.15  It manifests clinically in a variety of signs including weight loss, vomiting, 
inappetance, and anorexia.9, 29-31 Clinical symptoms are thought to be related to gastrointestinal 
lesions and the central effects of metabolic waste products.32  Toxins of uremia include products 
of protein catabolism and numerous other low, medium and large molecular weight proteins.15  
Theories on the mechanisms of injury include small molecular weight proteins acting on plasma 
membrane adenyl cyclase of gastric epithelial cells, generation of ammonia by gastric bacteria, 
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and altered blood flow with resultant local tissue hypoxia.33-35  Treatment in feline uremia is 
typically symptomatic and largely based on pathology in other species. 
1.2.2 Pathology of uremic gastropathy 
Uremic gastritis was first described in 1934 from autopsies in 135 uremic human patients; 
lesions varied from mild edema to hemorrhage, ulceration, and necrosis.36 In humans 
complications of uremia such as gastritis, ulceration, and hemorrhage are common.37 A 
descriptive study of gastric pathology in a small group of uremic dogs revealed marked lesions.33  
Half of the uremic dogs (n=2) had grossly identifiable lesion of the gastric mucosa in the fundus 
and body characterized by hemorrhage and ulceration.33  The cardia, antrum, and pylorus were 
spared.33  Histologically all uremic dogs were affected by lesions in the lamina propria, gastric 
glands, and submucosal vessels.  Vascular lesions of degeneration, necrosis, and mineralization 
were present with variable severity in all uremic dogs.  In addition, granular mineralization was 
present in the mucosa of uremic dogs.33 In a more recent study of gastric histopathologic features 
in uremic dogs, common lesions included edema, mineralization, glandular atrophy and 
vasculopathy.38  In this study lesions were present in 79% of dogs.  Of the dogs, 14% had 
evidence of gastric mucosal necrosis.38  Similar histopathologic studies have not been done in 
cats despite the high prevalence of renal disease in this species.  Studies of toxin ingestion such 
as Easter lily and melamine and cyanuric acid which resulted in renal failure were not associated 
with gastric ulceration.39, 40 
1.2.2 Gastrin and uremic gastropathy 
Gastrin is a hormone that stimulates the production of hydrochloric acid by gastric parietal cells 
in response to stomach distension or the presence of proteins.41, 42  Its release is under negative 
feedback regulation and thus is not secreted in the presence of acid in health.  In humans and 
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dogs, gastrin is excreted by the kidneys, and it is hypothesized that as renal function declines, 
hypergastrinemia develops, which could result in gastric hyperacidity.43 Hyperacidity can result 
in local tissue injury in the stomach; however, this appears to be an inconsistent finding.44  
Additional factors that potentially contribute to gastric lesions are thought to be the result of 
delayed gastric emptying and Helicobacter pylori infection.45-47   Gastric lesions have been 
reported in cats with hypergastrinemia  due to gastrin-secreting tumors but the relationship of 
hypergastrinemia as an etiology for gastric lesions or gastrointestinal symptoms in feline CKD 
has not been evaluated.48 
1.3 Alpha-enolase autoantibodies and kidney disease 
1.3.1 Renal immunity 
Resident leukocytes of the kidney include dendritic cells, macrophages, and lesser number of 
lymphocytes and mast cells.49, 50 Fibroblasts and dendritic cells are the most abundant cell type in 
the cortical and outer medullary interstitium.49 Low molecular weight proteins passing through 
the glomerular filtration barrier concentrate in proximal tubules where they are reabsorbed.  
Some proteins pass through tubules into the interstitium and are taken up by resident dendritic 
cells.  Interstitial dendritic cells can be exposed to 10-fold greater antigen levels in the kidney 
than any other tissue.50  Dendritic cells are largely responsible for antigen processing and 
presenting to regional lymph nodes and thus are a key player in immune tolerance.50, 51  
Additional functions include regulation of effector cells and production of pro-inflammatory 
cytokines (e.g. TNF) during renal injury.50, 52-54 Renal cortical macrophages are scarce but are 
associated with large vessels and are abundant in the renal pelvis.49  Macrophages function in 
tissue repair by removal of apoptotic cellular debris and production of growth factors as well as 
controlling infectious agents via phagocytosis and production of pro-inflammatory cytokines (IL-
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1β, IL-6, and TNF).52, 53, 55  Resident lymphocytes are present in low numbers while mast cells 
contribute to inflammation in some glomerulonephritides.50  
The intrinsic structural and functional properties of the kidney make it particular 
susceptible to injury.  The pattern of renal injury is largely influenced by the location and 
duration of the inflammatory stimulus.50  For example, immune complex deposition in glomeruli 
results in glomerulonephritis while ischemic, toxic, and obstructive etiologies will result in 
tubulointerstitial injury.50  These entities are not mutually exclusive and glomerulonephritis can 
lead to tubulointerstitial disease by various mechanisms such as injury to podocytes and other 
extracapillary components; ischemia secondary to post-glomerular capillary destruction; and 
tubular protein overload.13, 50, 56-59 
Autoimmune diseases are characterized by an adaptive immune response to self-antigen.  
The inciting trigger or target of said response is not entirely eliminated and thus leads to chronic 
inflammation and ultimately tissue injury.60, 61  Pathogenesis of autoimmunity, in general, is 
typical of any immune responses.  Either directly cytotoxic by activation of T lymphocytes or 
indirectly via initiation of humoral immunity by B lymphocytes.60, 62  Tolerance to self-antigens 
is established in the thymus by elimination of self-reactive T cells.  However, peptides with low 
affinity binding to T cell receptors are not as effective at driving this negative selection process.60  
Auto-reactive antibodies just like any other antibody are capable of forming immune complexes 
in circulation or react directly to tissue specific antigens in situ.63  The kidney is intrinsically 
susceptible to immune mediated injury by virtue of its structural composition. Immune complex 





1.3.2 Alpha-enolase: a target for autoantibodies  
Autoimmune disease can manifest systemically or be directed towards a specific organ.  In 
systemic autoimmune diseases, multiple body systems are affected.  Such is the case in systemic 
lupus erythematosus (SLE) in which several autoantibodies have been identified and typically 
target abundantly and ubiquitously expressed antigens.60, 68  However, some autoantibodies can 
be non-pathogenic and auto-reactive antibodies are present in healthy individuals.3, 69-71  The 
pathogenesis of antibody-mediated nephritis occurs by either deposition of circulating immune 
complexes or in situ binding of autoantibodies to self-antigen.3 Ultimately immune complexes 
will activate complement and recruit inflammatory cells leading to inflammation and tissue 
injury.  
Anti-α-enolase antibodies have been identified in a number of autoimmune diseases.72  
These antibodies were first described in patients with systemic rheumatic diseases a few decades 
ago.73  Currently anti-α-enolase have been reported in patients suffering from systemic lupus 
erythematosus, mixed cryoglobulinemia, systemic sclerosis, Behcet’s disease, and lymphocytic 
hypophysitis to name a few.74-79  Conversely, anti-α-enolase antibodies can also be found in 
healthy individuals with reports of prevalence ranging from 0-6% which may raise doubt as to 
the significance of this particular autoantibody.70, 72, 74, 79-82  However, in SLE and mixed 
cryoglobulinemia, α-enolase antibodies were associated with active nephritis with declining 
antibody levels after therapeutic commencement.75-77, 83  Furthermore, IgG and α-enolase were 
co-localized within glomeruli of patients with membranous glomerulonephritis and lupus 














The reactivity of autoantibodies to target antigens may give additional clues to the 
variability of antibody pathogenicity in individuals.  Patients with cancer-associated retinopathy 
syndrome, (CAR) a progressive retinal degenerative disease, develop anti-enolase antibodies.    
Epitope mapping of recombinant protein and anti-α-enolase sera from healthy and CAR patients 
revealed 3 common binding regions with an additional epitope unique to CAR patients.84  In 
addition, antibodies in CAR sera had cytotoxic effects on in vitro retinal cells not observed in 
healthy controls.  This suggests that not all autoantibodies are equivalent and that specific 
epitope recognition may confer pathogenicity. 
In addition to autoimmune diseases, α-enolase antibodies have been associated with few 
infectious diseases.  Alpha-enolase antibodies were found in 99% of children that presented for 
Streptococcus pneumonia otitis media.85  Anti-α-enolase antibodies limit tissue invasion by 
Streptococcus pyogenes and is a major cell surface protein of group A Streptococci.86, 87  It is 
 
Figure 1.1 Immunofluorescence of glomerular α-enolase (a) and IgG4 (b) co-localized 
(merged, c) in membranous glomerulonephritis.  Scale bar=20 μm, x630.  Adapted 
from “Direct characterization of target podocyte antigens and auto-antibodies in 
human membranous glomerulonephritis: Alfa-enolase and borderline antigens.” M. 
Bruschi, 2011, J Proteomics, 74(10), 2008-2017. Copyright by Elsevier. Adapted 
with permission. 1 
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likely that the homologous nature of α-enolase between eukaryotes and prokaryotes contributes 
to the cross reactivity of antibodies via molecular mimicry.61, 68, 72, 85   
1.3.3 Alpha-enolase autoantibodies in the cat 
Crandell Rees Feline Kidney (CRFK) cell lysate was established five decades ago as the first 
feline cell line to successfully be maintained in continuous culture.88  CRFK cell lysates were 
derived from the renal cortex of a young domestic cat and morphologically described in culture 
as “epithelial-like”.88  Designed for feline viral research, CRFK cells are susceptible to feline 
picornaviruses, reovirus, panleukopenia, and herpesvirus 1 which makes them ideal for the 
manufacturing of the core, prophylactic vaccine used routinely to immunize cats against feline 
herpesvirus 1 (rhinotracheitis), calicivirus, and panleukopenia virus (FVRCP).88-91  Since the 
establishment of CRFK cells for replication of feline viruses other cell lines have been explored 
and utilized for research and vaccine purposes.89, 92  Exclusion of all cellular constituents or 
proteins from the purification of viruses used in vaccines is improbable; therefore, cats may be 
exposed repeatedly to feline cellular antigens over the course of a lifetime from the 
administration of any parenteral vaccine that are developed in feline cell culture.    
To determine if vaccine or the cell lysate could induce antibodies or renal injury, cats 
were hyperinoculated with FVRCP vaccine or CRFK cell lysates.91  A total of 4 FVRCP 
vaccines or 11 lysate inocula at 10 μg, 50 μg, or 50 μg with aluminum adjuvant were 
administered to a number of individual cats over 50 weeks.  Serial serum samples were 
monitored for antibodies against CRFK or feline renal cell (FRC) lysates using tissues from 
specific pathogen free (SPF) cats.  All cats that were hyperinoculated with cell lysates developed 
antibodies targeted against cell lysate (CRFK and FRC).  Five of the 6 cats that were 
administered parenteral FVRCP vaccine developed antibodies against CRFK lysate with all 
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developing antibodies against FRC lysate antigen.  Cats that were administered vaccine 
subcutaneously had significantly higher levels of antibodies than cats that were administered an 
intranasal vaccine.  CRFK antigens recognized by vaccine induced antibodies were determined 
by immunoassays, affinity chromatography, and proteomics from cats administered FVRCP 
vaccination or CRFK lysates.93  Sera from the majority (8/14) of cats from either inoculation 
group had anti-α-enolase antibodies.  Post-inoculation sera from cats administered FVRCP 
vaccines parenterally had significantly greater amounts of CRFK and α-enolase antibodies by 
enzyme-linked immunosorbent assay (ELISA).93 In a separate study, azotemic cats with 
naturally occurring renal disease had significantly higher levels of α-enolase antibodies than non-
azotemic cats.94 
Study cats that were hyperinoculated with either vaccine or cell lysates were biopsied.   
Two cats, 1 that received CRFK lysate and another parenteral FVRCP vaccine, developed mild 
interstitial inflammation by the end of the study.91  A year later, cat’s hyperinoculated with 
CRFK lysate were administered a booster and then biopsied 2 weeks later.  Of these 6 cats, 3 
developed interstitial nephritis (Figure 1.2).4  Glomerular lesions or ultrastructural immune 
complexes were absent.  Lesions present in the biopsies of these 3 cats are similar to the 
histologic changes encountered in feline CKD which includes interstitial mononuclear 
inflammation and tubular injury with relative sparing of glomeruli typical of chronic interstitial 
nephritis.7, 8, 15, 95  This pattern of injury however is not specific to a particular cause but rather a 
common end result of multiple etiologies.15  In a majority of cats with CKD and the 3 
hyperinoculated cats with interstitial nephritis in the aforementioned study; primary glomerular 
lesions, or ultrastructural evidence of immune-complexes in the latter, were not present.  Based 
on these observations an immune-complex mediated pathogenesis, such as with lupus nephritis, 
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is unlikely in the hyperinoculated cats.   However, induction of auto-antibodies by 
hyperinoculation with parenteral vaccination or cell lysate; and the significant levels of α-enolase 
antibodies in azotemic cats are suggestive of a role of these antibodies in feline renal disease and 




Figure 1.2  Biopsy from a cat hyperinoculated with CRFK lysates. Marked 
mononuclear interstitial inflammation with tubular loss. Hematoxylin and eosin, 
20X. Adapted from “Interstitial nephritis in cats inoculated with Crandell Rees 
feline kidney cell lysates” M. Lappin, 2006, J Feline Med Surg, 8(5), 353-356. 
Copyright by SAGE publishing. Adapted with permission4 
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1.4 Alpha-enolase in health and disease   
1.4.1 Alpha-enolase the glycolytic enzyme 
Alpha-enolase (2-phospho-D-glycerate hydrolyase) is a metal-ion-activated enzyme that 
catalyzes the dehydration of 2-phosph-D-glycerate to phosphoenolpyruvate in the catabolic 
direction of the Emden Mayerhoff-Parnas glycolytic pathway.87, 96  Enolase is capable of 
catalyzing the reverse reaction--hydrolysis of phosphoenolpyruvate--during gluconeogenesis 
(anabolic pathway).  Six divalent metal ions can activate this enzyme; however magnesium is its 
natural cofactor.97, 98   
An abundantly expressed cytosolic protein, enolase exists as 3 isoenzymes:  α-, β-, and γ-
isoforms.99-102  The α-isoform is found in a variety of tissues, β-isoform is almost exclusively 
found in muscle, and γ-isoform is primary found in neural and neuroendocrine tissues.  Three 
independent genetic loci encode for each individual isoenzyme.87, 99-103  All enolase are made up 
of 2 identical subunits (dimer) and have a molecular weight of 82,000-100,000 Da.87  The amino 
acid sequence of enolase is highly conserved across species.87  Gene expression of enolase is 
variable depending on the pathophysiologic, metabolic, or developmental conditions of the cell 
and therefore not considered a housekeeping gene.104  ENO1 encodes for α-enolase in addition to 
the DNA-binding tumor suppressor protein, c-myc binding protein (MBP-1). MBP-1 is shorter, 
37 kDa as opposed to α-enolase which is 48 kDa, and is mostly located within the nucleus.105  
1.4.2 Alpha-enolase protein in disease 
Alpha-enolase is not restricted to the cytoplasm as a glycolytic enzyme.  This protein has been 
identified in the pathogenesis of several infectious, inflammatory, and neoplastic diseases.87   
Cardiac isoforms are altered during hypertrophy and subject to post-translation modifications in 
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diabetes.106, 107   Alpha-enolase can be externalized on the cell surface as a marker for apoptosis 
or act as a plasminogen receptor on the cell membrane.108, 109  It promotes tumor cell survival 
during anaerobic conditions and aids in tumor invasion.109   
Up regulation in α-enolase protein expression has been described in several diseases.  
Renal α-enolase protein expression was assessed by immunohistochemistry utilizing an anti-α-
enolase IgG1 monoclonal antibody purified from immunized BALB/c mice.3 Renal biopsies 
from systemic lupus erythematosus (SLE) patients with lupus nephritis and healthy individuals 
were assessed for protein expression.  In healthy controls, alpha-enolase was highly expressed in 
tubules but absent in glomeruli.  In biopsies from patients with lupus nephritis tubular α-enolase 
was greater than controls and glomerular expression was up regulated.  Mesangial cells, parietal 
and visceral epithelial cells as well as cellular crescents in glomeruli expressed protein where it 













Figure 1.3 Immunohistochemistry for α-enolase from a renal biopsy from a patient with 
systemic lupus erythematous.  High expression in tubules and glomeruli, monoclonal 
mouse α-enolase antibody. Adapted from “The targets of nephritogenic antibodies in 
systemic autoimmune disorders” P. Migliorini, 2002, Autoimmune Rev,1(3),168-173. 
Copyright by Elsevier. Adapted with permission.3  
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In a separate immunohistochemical study of renal enolase expression in the tubules of 
renal adenocarcinoma it was shown that α-enolase was preferentially expressed.110  Alpha-
enolase was strongly expressed in proximal tubules, collecting ducts, and distal tubules in 
healthy controls.  Protein expression was not found in the loops of Henle.  Gamma-enolase was 
localized to macula densa cells, occasionally in the collecting ducts, distal tubules and 
Bowman’s capsule but not in the proximal tubules.  In the medulla, γ-enolase was found in most 
of loops of Henle and collecting ducts but only a few distal tubules.  Both isoforms were 
localized to the cytoplasm and occasionally the nucleus.  Protein concentrations determined by 
immunoassay were greater for α-enolase than γ-enolase.  Levels of γ-enolase in the medulla were 
statistically higher than those in the cortex.  Both isoforms were greater in renal cell carcinoma 
cells than controls.110 
Alpha-enolase protein may also serve as a marker for physiologic stress.109 Adverse 
environmental conditions such as elevated temperatures and glucose depletion may induce 
cellular synthesis of heat shock proteins (HSP) and glucose-regulated proteins (GRP), 
respectively.  In addition endothelial cells exposed to hypoxic conditions in vitro can synthesize 
a distinct set of hypoxia-associated proteins (HAPS; Mr 34, 36, 39, 47, and 56 kDa).111, 112  This 
appears unique to endothelial cells as primary cultures of mouse renal tubular epithelial cells did 
not up regulate any specific proteins during hypoxic conditions.  However, a majority of renal 
tubular cells did not survive to the time point of maximal protein up regulation of other cell types 
(≥18 hours).  Endothelial cells appear to be tolerant of hypoxic conditions due to up regulation of 
HAPs while renal tubular epithelial cells are extremely sensitive.112  Furthermore, the 47 kDa 
HAP protein from hypoxic endothelial lysates were isolated and sequenced.  Significant identity 
was found with the glycolytic enzyme enolase (75% homology to human α-enolase).  This 
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suggests that α-enolase can function as a hypoxic-associated protein aiding in the survival of 
endothelial cells during hypoxia.113 
1.5 Membranous cellular localization of alpha-enolase  
1.5.1 Surface expression in autoimmune disease  
A feature of systemic autoimmune disorders is production of antibodies specific for antigens 
which are often highly conserved structures and are frequently enzymes.114  Alpha-enolase 
antibodies are present in sera of patients with mixed cryoglobulinemia (MC), SLE, and systemic 
sclerosis.3, 74, 114  In patients with SLE and MC the presence of antibodies invariably was 
associated with active nephritis.  Alpha-enolase has been described as a multifunctional protein 
because of its variable cellular distribution and interaction with other cellular components.109  In 
an experiment by Moscato et al. fractionated renal cortical cells were utilized to determine α-
enolase cellular location and assess the interaction of spontaneous and induced anti-α-enolase 
antibodies.114 Mouse monoclonal antibodies and antibodies isolated from MC, SLE, and SSc 
patients bound to membranous α-enolase by immunoprecipitation and inhibited binding of 
plasminogen.  These data suggests a pathogenic role of anti-α-enolase antibodies in autoimmune 
disease by interfering with the function of membranous α-enolase as a plasminogen receptor.   
  Systemic sclerosis is a connective tissue disorder characterized by excessive fibrosis of 
organs.115, 116  A majority of individuals have detectable antinuclear autoantibodies.115 These 
autoantibodies are capable of activating fibroblasts in vitro.116  Indirect immunofluorescence 
with IgG from systemic sclerosis patients (antifibroblast antibodies, AFA) demonstrated 
significant reactivity to the plasma cell membrane of skin fibroblasts.  Fibroblasts exposed to 
AFA IgG had a dose-dependent up-regulation of cell surface ICAM-1expression and IL-6 
production.  In addition AFA IgG up-regulated cytokine gene expression (IL-1α, IL-1β, and IL-
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6).  Alpha-enolase was identified as a major target of AFA IgG by immunoblot and ELISA.115  
These findings show that α-enolase is expressed on the cell surface of fibroblasts and act at some 
capacity in cell signaling which may contribute to the fibrotic phenotype in this disease. 
1.5.2 Alpha-enolase: plasminogen receptor 
Plasminogen receptors are a heterogeneous group of proteins that contain a carboxyl-terminal 
lysine.3  It is highly expressed and ubiquitously distributed on various cell types.3  The 
importance of α-enolase as a plasminogen receptor has been determined in several diseases.  On 
the surface of leukocytes, neuronal and endothelial cells α-enolase can function as a plasminogen 
receptor.109, 117-121  Cell membrane expressed α-enolase is structurally distinct from other 
enolases despite high sequence similarities which may explain its multifunctionality.122  As a 
plasminogen receptor, activation of plasminogen is enhanced and plasmin is protected which 
ultimately promotes fibrinolysis and degradation of extracellular matrices.109  In autoimmune 
disorders resulting in nephritis, such as previously discussed in lupus nephritis patients, 
autoantibodies target are known to target glomerular α-enolase.3, 83  It has been proposed that the 
mechanism of injury in this disorder is interference of α-enolase that is functioning on the cell 
membrane as a plasminogen receptor.  Blocking potential plasminogen binding sites would 
impair fibrinolysis promoting inflammation and tissue injury.3  Therefore, membranous α-
enolase functioning as a plasminogen receptor could be blocked by autoantibodies and thus 
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CHAPTER 2:  RESEARCH OVERVIEW AND SPECIFIC AIMS 
 
2.1 Research Overview 
Chronic kidney disease (CKD) has been reported in 28-50% of cats and increases in prevalence 
with age.1-3  It is characterized by a reduction of structural and functional components resulting 
in retention of metabolic waste products, decreased urinary concentrating ability, electrolyte and 
acid-base imbalances.3-5  The most frequent morphologic diagnoses in cats with CKD are chronic 
tubulointerstitial nephritis and fibrosis; which are relatively non-specific lesions.4, 6, 7 Fibrosis is 
considered a common end point of all kidney diseases which does little to aid the clinician in 
determining an inciting cause.8  Frequently, CKD in cats is considered multifactorial resulting in 
progressive, irreversible kidney damage.5 Etiologies that have been proposed to contribute to 
renal injury in cats include Leptospira species, feline morbillivirus, diet, age, and vaccines; 
however, definitively defining the etiopathogenesis of CKD has not been accomplished in this 
species. 6, 9-12 
The goal of this dissertation is twofold.  First to better characterize renal pathology in 
feline CKD and associated gastric lesions histologically.  These aims are covered in Chapters 3 
and 4, respectively.  The second goal of this dissertation is to evaluate the expression of renal α-
enolase and its potential role as a target for circulating autoantibodies in cats with CKD.  These 
aims will be addressed in Chapters 5, 6, and 7. 
2.2 Specific Aim 1 (Chapter 3: Histopathology of CKD IRIS stages) 
Histologically tubulointerstitial nephritis is the most common diagnosis made in association with 
feline CKD.4  This common lesion can be result of numerous renal insults however and is not 
indicative of any particular etiology.4, 6, 7  The cause of CKD in cats frequently cannot be 
determined at the time of diagnosis and often renal injury is significant and irreversible.4, 5, 13   
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Staging feline CKD was established by the International Renal Interest Society (IRIS) 
based on measurement of serum creatinine concentrations and further sub-staged by the presence 
of hypertension and proteinuria.14, 15  These clinicopathologic parameters are useful for 
diagnosing, staging, and prognosticating but give few clues as to the distribution and pattern of 
injury within the kidney at individual stages. Therefore it is difficult to determine which stages 
are characterized by irreversible lesions and at which stage interventional therapies should be 
targeted. 
The objective of aim 1 is to characterize and quantify interstitial, tubular, glomerular and 
vascular lesions in the kidney of cats with CKD and assess the association between these 
histopathologic changes and clinical IRIS stage and sub-stage.  The hypothesis for this aim is 
that histopathologic lesions in the kidneys of cats with CKD will vary between clinical IRIS 
stages.  Renal tissue from cats at various IRIS stages were systematically evaluated and scored 
on defined histopathologic criteria by two pathologists.  Histologic scores and clinicopathologic 
data are compared between groups.  Young and geriatric, non-azotemic cats are included as 
controls. 
2.3 Specific Aim 2 (Chapter 4: Uremic gastropathy) 
Uremia is a consequence of renal insufficiency with retention of metabolic waste products 
manifesting in clinical symptoms which can include weight loss, vomiting, inappetance and 
anorexia. 16-19 Such clinical presentations are often thought to be the result of gastric hyperacidity 
secondary to hypergastrinemia and gastric pathology.20, 21  However, while this pathogenesis 
may hold true in human patients with uremia little has been described as to the presence or 
contribution of gastric lesions to clinical symptoms in feline patients suffering from renal 
28 
 
disease.22  While hypergastrinemia has been shown to be associated with severity of feline CKD, 
the presence of gastric lesions have not assessed.20 
The objectives of aim 2 is to evaluate the type and prevalence of histopathologic lesions 
in the stomach of cats with CKD, and to determine whether the degree of azotemia, calcium-
phosphorus products and serum gastrin concentrations correlate with gastric pathology. The 
hypothesis for aim 2 is that uremic gastropathy is an uncommon finding in cats with CKD.  
In this chapter, gastric and renal tissues from cats at various stages, or severity, of renal disease 
and healthy controls are systematically evaluated and scored on defined histopathologic criteria 
by two pathologists.  In addition, histologic scores are compared to clinicopathologic parameters 
such as serum creatinine, calcium-phosphorus product, and gastrin concentrations. 
2.4 Specific Aim 3 (Chapter 5: Alpha-enolase antibodies in serum) 
Core vaccines routinely administered to cats and the cell lysates used in vaccine production have 
been associated with development of antibodies against these lysates and renal disease 
experimentally.12, 23  Crandell Rees feline kidney (CRFK) cell line originated from renal cortical 
tissue of a young, healthy domestic cat.24  Established cell cultures were described 
morphologically as “epithelial-like” and are used for production of the core feline herpesvirus 1, 
calicivirus, and panleukopenia (FVRCP) vaccine.23-26  Inevitably these cell contaminates are 
included in the vaccine therefore exposing cats to feline cellular proteins repeatedly over a 
lifetime.23  An immunodominant protein, α-enolase, was identified as a target antigen for vaccine 
and CRFK lysate induced antibodies in cats that were administered repeated boosters.27   
Anti-α-enolase antibodies present in sera are associated with a myriad of infectious, 
autoimmune, inflammatory, and degenerative diseases.28-30  Of particular interest, podocyte α-
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enolase has been found to be the target of auto-antibodies in membranous glomerulonephritis 
and lupus nephritis.31, 32  While the presence of autoantibodies to this particular protein has been 
defined in numerous disease states, the genesis of antibody production is largely undefined in 
human patients.29 
The objective of this dissertation chapter is to identify and quantitate anti-α-enolase 
antibodies in cats with naturally occurring CKD.  Additionally, to identify possible endogenous 
proteins targeted by autoantibodies. The hypothesis for aim 3 is that anti-α-enolase antibodies 
will be present in sera of cats with naturally occurring CKD and that these antibodies will 
bind to endogenous feline renal α-enolase protein.  Anti-α-enolase antibodies are assessed by 
western blot immunoassay and quantitated by an enzyme-linked immunosorbent assay (ELISA) 
against recombinant α-enolase protein.  Additionally, immunoglobulin is extracted from sera by 
a traditional immunoprecipitation assay from azotemic and non-azotemic cats with or without α-
enolase antibody confirmed by western immunoblot.  This immunoglobulin is then used to target 
and identify specific endogenous renal antigens by gel electrophoresis and mass spectrometry, 
respectively.  Serum from cats with naturally occurring CKD at IRIS stages II-IV and healthy, 
non-azotemic young cats have been included in this study.   The healthy, laboratory reared 
control cats have not been administered parenteral vaccines containing viruses grown on cells.  





2.5 Specific Aim 4 (Chapter 6: Renal α-enolase protein expression) 
Originally characterized as a cytoplasmic, glycolytic enzyme, α-enolase has been shown to have 
multiple functions as well as variable cellular expression.33-35  This protein is ubiquitously 
expressed but most concentrated in the thymus and kidney.36  In the kidney α-enolase is localized 
to the cytoplasm of renal proximal tubules, collecting ducts, and distal tubules.30, 37  In human 
patients with lupus nephritis, an autoimmune disease associated with the presence of 
autoantibodies in sera, α-enolase protein expression is altered.  In biopsies from lupus nephritis 
patient’s α-enolase is overexpressed in tubules and glomeruli in comparison to healthy controls.30  
Similar descriptive studies of α-enolase protein expression have not been explored in cats with or 
without CKD. 
The objective of aim 4 is to semi-quantitate α-enolase protein expression within tissues of 
cats in health and with CKD.  The hypothesis for aim 4 is that tubular and glomerular α-
enolase will be overexpressed in cats with CKD.  In order to test this hypothesis, 
immunohistochemistry utilizing a mouse monoclonal antibody will be optimized and validated.  
Kidney and liver tissue from cats with CKD and healthy, non-azotemic controls are included in 
this study.  Thymic tissue from a young cat will be used to optimize and validate this assay. 
2.6 Specific Aim 5 (Chapter 7: Cellular expression and antigenicity of renal proteins) 
Autoimmune disease is characterized by dysregulation of the immune system and loss of self-
tolerance.38  Targets of autoantibodies are frequently conserved, abundantly expressed proteins.34  
Examples include topoisomerase in systemic sclerosis, insulin in type I diabetes, and α-enolase 
in systemic lupus erythematosus.34, 38-40  Anti-α-enolase antibodies can be induced 
experimentally in cats with feline panleukopenia, herpesvirus 1, and calicivirus containing viral 
vaccines.23, 27  These vaccines (FVRCP) are routinely administered to cats and can contain cell 
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lysate contaminates (CRFK) that originated from cat renal cortical tissue.23, 24  Feline renal 
derived cell lysates—CRKF lysates—not only can induce production of antibodies to α-enolase 
but led to interstitial nephritis in a subset of cats.12, 27  Furthermore, client owned cats with 
azotemia were more likely to have anti-α-enolase antibodies than non-azotemic client owned cats 
(Chelsea Sonius, unpublished work).41 Cellular expression of α-enolase is not restricted to the 
cytosol with membranous α-enolase targeted by autoantibodies in autoimmune disease as well as 
alternative, non-glycolytic functions.34  
The objective of this chapter is to localize cellular expression of α-enolase in renal tissue 
homogenates from cats with CKD.  The hypothesis for aim 5 is that α-enolase will be present 
in both cytosolic and membranous fractions in cats with CKD.  Identification of α-enolase 
protein in subcellular fractions of whole renal tissue homogenate from cats with CKD and young 
healthy controls will be achieved by differential centrifugation (herein referred to as subcellular 
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CHAPTER 3:  A COMPARISON OF BIOCHEMICAL AND HISTOPATHOLOGIC STAGING 
IN CATS WITH CHRONIC KIDNEY DISEASE 
3.1 Chapter Summary  
 Chronic kidney disease (CKD) is prevalent in elderly cats.  Frequently, a diagnosis is 
made in later stages of disease by which time many renal lesions are irreversible.  As such, little 
headway has been made in identifying an etiology and preventing this common disease. The aim 
of this study was to evaluate the presence and severity of both reversible and irreversible 
histopathologic changes in the kidneys of cats at each stage of CKD and in addition, to determine 
if lesion prevalence and character was different between stages.  A total of 46 cats with CKD 
were classified according to the International Renal Interest Society (IRIS) as: Stage I (3 cats), 
Stage II (16 cats), Stage III (14 cats), and Stage IV (13 cats).  Eleven young, non-azotemic and 
10 geriatric, non-azotemic cats were included as controls.  The severity of tubular degeneration, 
interstitial inflammation, fibrosis, and glomerulosclerosis was significantly greater in later stages 
of CKD compared to early stages of disease. Proteinuria was associated with increased severity 
of tubular degeneration, inflammation, fibrosis, tubular epithelial single cell necrosis and 
decreased normal parenchyma. Presence of hyperplastic arteriolosclerosis, fibrointimal 
hyperplasia, or other vascular lesions was not found to be significantly different between 
hypertensive and normotensive cats. The greater prevalence and severity of irreversible lesions 
in Stage III and IV CKD implies that therapeutic interventions should be targeted at earlier 
stages of disease.  
3.2 Introduction 
Chronic kidney disease (CKD) affects as many as 50% of elderly cats, and prevalence 
increases with age.1, 2 The etiology of CKD in cats is unknown. In humans, the leading cause for 
end stage renal failure is type 2 diabetes mellitus and hypertension.3 However, diabetic 
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nephropathy has not been identified in cats and renal lesions in diabetic cats were no different 
than those in non-diabetic cats.4 The most frequent morphologic diagnosis in cats with CKD is 
chronic tubulointerstitial nephritis and fibrosis; which are relatively non-specific lesions.5-7 
Therefore, feline CKD is currently considered to be the consequence of a variety of etiologies 
that lead to a final common pathway of irreversible, progressive, kidney damage.8 This damage 
culminates in reduction of glomerular filtration rate which, when severe, results in retention of 
metabolic byproducts such as creatinine and blood urea nitrogen. Eventually, uremia may 
develop and manifest as gastrointestinal, cardiovascular, pulmonary, neuromuscular, or 
hematologic diseases.8, 9    
CKD is categorized into disease stages established by the International Renal Interest 
Society (IRIS) based on serum creatinine measurements.10, 11 Clinical progression, or stage, is 
associated with decreased survival.12 Clinicopathologic data are useful for diagnosing, staging, 
and prognosticating but gives few clues as to the distribution and pattern of injury within the 
kidney. Therefore it is difficult to determine which stages are characterized by irreversible 
lesions and at which stage interventional therapies should be targeted.  In a previous study, renal 
fibrosis in cats with CKD from the United Kingdom correlated with clinicopathologic 
derangements such as azotemia, hyperphosphatemia, and anemia.7 Renal scarring encompasses 
interstitial fibrosis, which is an increase in extracellular matrix, as well as glomerulosclerosis and 
tubular atrophy.13-16 Collectively, these changes imply a loss of function and are considered, at 
least to date, irreversible.15, 16 However, not all injury leads to irreversible damage. Replication 
and repair can lead to a return of normal function. Inflammation, edema and tubular epithelial 
damage have the potential to resolve (i.e. reversible). Interest in these types of morphologic 
responses guided the design of this study. The aim of the current study was to further explore the 
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relationship between clinical parameters and renal pathology by characterizing and quantifying a 
wide variety of interstitial, tubular, glomerular and vascular lesions (both reversible and 
irreversible) in the kidney of cats with CKD from the United States and assessing the correlation 
between these histopathologic changes and clinical IRIS stage and substage. 
3.3 Materials and Methods 
3.3.1 Case Selection 
Cats necropsied at Colorado State University Diagnostic Medical Center between 2000 and 2013 
with a history of CKD, appropriate clinicopathologic data necessary for IRIS staging, and 
adequate tissue available for histologic review were included in this study. Exclusion criteria 
included renal neoplasia, ureteral or urethral obstruction, or pyelonephritis. Non-azotemic 
geriatric cats were humanely euthanized with client consent for health problems unrelated to 
renal disease. Young non-azotemic cats were euthanized at a local humane society, according to 
humane society guidelines and protocols. Study samples were obtained from these cats after 
euthanasia, and no cats were euthanized for the purpose of this study. Age was estimated by 
surrender history and/or dental assessment.  
3.3.2 Clinicopathologic Data 
Using the IRIS staging scheme, patients (designated CKD cats) were assigned a Stage of I to IV 
based on clinical evaluation of the cat’s medical history by a board-certified internist. Clinical 
evaluation for IRIS stage determination took into account 2 or more serum creatinine levels no 
less than 48 hours apart, clinical history, fluid therapy, body condition score and fluctuation in 
weight and muscle mass over the course of the disease. Patients assigned to Stage I had a urine 
specific gravity (USG) < 1.035, serum creatinine less than 1.6 mg/dl, as well as other evidence of 
renal abnormalities such as abnormal imaging (radiograph and/or ultrasound), and/or proteinuria. 
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Stages II, III, and IV were defined by creatinine measuring 1.6-2.8 mg/dl, 2.9-5.0 mg/dl and >5.0 
mg/dl, respectively. Non-azotemic control cats had no clinical evidence or history of renal 
disease, USG >1.035, and creatinine ≤ 1.6 mg/dl. Control cats were divided into either non-
azotemic geriatric controls (GC) if they were ≥7 years of age or non-azotemic young controls 
(YC) if they were <4 years of age. 
Substaging according to proteinuria and elevation of systemic blood pressure was 
determined based on data availability. Urine samples were collected via cystocentesis during 
routine examination and submitted to the Clinical Pathology Laboratory at Colorado State 
University Diagnostic Medical Center. Quantification of urine protein was determined by urine 
protein to creatinine ratio (UPC) measurement and only CKD cats in which UPC data were 
available were included in this portion of the analysis. GC cats were confirmed to have no 
urinary protein by the sulfosalicyclic acid precipitation test. Hypertension was determined by 
repeated mean systolic blood pressure measurements of greater than 160 mm Hg, prior clinical 
diagnosis of hypertension, or evidence of hypertensive therapy (e.g. amlodipine) in the medical 
record; only cats with blood pressure data available were included in this portion of the analysis. 
3.3.3 Histopathology 
Tissues were preserved in 10% neutral buffered formalin, routinely processed, and embedded in 
paraffin. Sections of kidney cut at 3 μm and stained with hematoxylin and eosin, periodic acid-
Schiff-hematoxylin to assess basement membranes of tubules and blood vessels, and Masson’s 
trichrome for assessment of fibrosis. Tissues were evaluated for a range of histologic lesions by 
two pathologists. The scoring schematic for dichotomous and semi-quantitative histologic 
variables is outlined in Table 3.1. Additionally, continuous variables included global 
glomerulosclerosis and frequency of tubular epithelial single cell necrosis. Global 
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glomerulosclerosis was determined by examining 50 randomly distributed glomeruli per kidney 
to determine the proportion in which >75% of the capillary tuft was effaced by extracellular 
matrix. When present, specific glomerular lesions (e.g. glomerulonephritis or focal segmental 
glomerulosclerosis) were noted.  As renal lesions can be unilateral, if both kidneys were 
available, each was scored separately for the following variables: percent normal parenchyma, 
interstitial cortical scarring, medullary scarring, interstitial inflammation, tubular epithelial single 
cell necrosis, and globally sclerotic glomeruli. Scarring was defined as a percentage of cortex or 
medulla occupied by trichrome-confirmed collagenous matrix, in conjunction with fibroplasia, 
parenchymal collapse due to tubular atrophy and loss and glomerulosclerosis.13, 14  Vasculature 
was assessed for degenerative changes, specifically arteriolosclerosis.  Evaluation of 
arteriolosclerotic lesions included: concentric medial smooth muscle hyperplasia (hyperplastic 
arteriolosclerosis); or segmental or circumferential intimal proliferation with disruption of the 
internal elastic lamina (fibrointimal hyperplasia). Other vascular lesions (eg fibrinoid vascular 














3.3.4 Statistical Analysis 
A univariate approach was used to determine if histologic variables differed between non-
azotemic cats and those with CKD. Serum creatinine, IRIS stage, and proteinuria status were 
designated as independent variables.  For semi-quantitative outcome variables (e.g. pattern of 
interstitial scarring) medians were reported and data were converted into ‘ranks’ for linear 
regression analysis. For variables with multiple measurements from the same individual (i.e. 
both kidneys available for review) repeated measures were taken into account for regression 
analyses. Similarly, for continuous variables, differences in means among groups were 
determined by linear regression after assumptions for normality were confirmed. Fisher’s exact 
test was used for dichotomous variables and odds ratios were calculated with 95% confidence 
interval. Statistical significance for all analyses was set at p≤0.05 and p≤0.0125 for pairwise 
comparison to account for multiple comparisons. Statistical calculations were performed by SAS 
v9.3 (SAS Institute Inc., Cary, NC, USA). 
3.4 Results 
3.4.1 Signalment 
Of 331 CKD cats necropsied between 2000 and 2013, a total of 46 CKD cats had sufficient 
clinical data and tissue for evaluation. Age, sex, and cause of death are outlined in Table 3.2.  
There was no statistically significant difference among groups with regards to gender or breed.  
Two CKD cats included in this study died of natural causes while the remaining cats were 
humanely euthanized. Those euthanized for poor quality of life or acute decompensation of CKD 














Twenty-five cats were euthanized for reasons not directly related to kidney disease, 
including:  neoplasia (n=9); gastrointestinal disease, liver disease, or pancreatitis (n=5); and 
cardiopulmonary disease (n=4) which included congestive heart failure, thromboembolism, or 
pulmonary disease. The remaining CKD cats were euthanized for a variety of metabolic or 
neurologic illnesses (n=7). Five of the 10 GC cats were euthanized for non-renal neoplasia; 4 





Controls Stage 1 Stage 2 Stage 3 Stage 4
(n=11) (n=10) (n=3) (n=16) (n=14) (n=13)
Age (years)a 3 (1-4) 13 (10-16) 11 (9-15) 15 (8-21) 14 (5-19) 11 (5-18)
Cause of 
death/Euthanasia
Kidney disease 0 0 0 2 7 12
Non-renal disease 0 10 3 14 7 1
1.16 1.23 1.38 2.12 4.31 8.18
Creatinineb (0.8-1.5) (0.9-1.5) (1.35-1.4) (1.5-2.7) (2.95-9.1) (6.0-12.65)
1.067 1.054 1.031 1.018 1.015 1.011
USGc (1.049-1.084) (1.044-1.067) (1.025-1.035) (1.012-1.032) (1.010-1.020) (1.007-1.015)
Proteinuria
Staged n=11 n=10 n=1 n=13 n=7 n=12
UPC <0.2  11 (100) 10 (100) 1 (100) 11 (85) 1 (14) 3 (25)
UPC 0.2-0.4  0 0 0 2 (15) 5 (72) 1 (8)
UPC >0.4   0 0 0 0 1 (14) 8 (67)
Hypertensivee n/df n/d 1 (100) 6 (50) 2 (22) 4 (36)
aMean age in years (range) 
 bAverage of two serum creatinine measurements taken prior to euthanasia in CKD cats (range of  
creatinine for each group) 
cMean (range) 
dNumber of cats with proteinuria per group (percentage of cats with available UPC data); Non- 
proteinuric <0.2, Borderline proteinuric 0.2-0.4, and Proteinuric >0.4 
eNumber of hypertensive cats per stage (percentage of hypertensive cats with available systolic blood  
pressure) 




Statistically significant variables are outlined in Tables 3.3 and 3.4 for all CKD stages. The 
salient features of each stage are described below, with special attention being paid to the lesions 
deemed to have pathophysiologic relevance. Results for categorical variables for each group are 






Figure 3.1  Graph of categorical histologic variables by group (YC=young controls; GC=geriatric 
controls) or chronic kidney disease (CKD) stage. Columns represent mean percentage of tissue 


















































































































































Table 3.4  Categorical histologic variables with statistical significance.  For each stage the 
median, mean, and range for each variable are given along with p-values.  Bolded p-values 
indicate statistical significance when compared to other groups by linear regression of ranks. 
Tubular 
compartment Other
% Inflammation % Cortical scar % Medullary scar % Degneration % Normal
Stage I (n=3 ) 1 (1.2, 1-2)a 0 (0.2, 0-1) 0 (0.2, 0-1) 1 (1, 1-1) 3 (3, 3-3)
vs YC 0.0041 0.9307 0.3074 0.253 n/ab
vs GC 0.4082 0.1105 0.9585 1 <0.0001
vs Stage II 0.9429 <0.0001 0.0069 0.1545 0.818
vs Stage III 0.0123 <0.0001 0.0039 0.0069 0.003
vs Stage IV <0.0001 <0.0001 0.0032 0.0001 <0.0001
Stage II (n=16 ) 1 (1.2, 1-3) 1 (1.4, 1-3) 1 (0.9, 0-2) 1.5 (1.6, 0-3) 3 (2.9, 1-4)
vs YC <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
vs GC 0.2136 <0.0001 0.0005 0.0263 <0.0001
vs Stage I 0.9429 <0.0001 0.0069 0.1545 0.818
vs Stage III <0.0001 0.4513 0.7564 0.0247 0.0404
vs Stage IV <0.0001 0.0001 0.5705 <0.0001 <0.0001
Stage III (n=14 ) 2 (1.9, 0-4) 1 (1.6, 0-4) 1 (1.1, 0-4) 2.5 (2.1, 0-3) 2 (2.2, 1-4)
vs YC <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
vs GC <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
vs Stage I 0.0123 <0.0001 0.0039 0.0069 0.003
vs Stage II <0.0001 0.4513 0.7564 0.0247 0.0404
vs Stage IV 0.0259 0.008 0.7795 0.062 0.0062
Stage IV (n=13 ) 3 (2.7, 1-4) 2 (2.3, 1-4) 1 (1.3, 0-4) 3 (2.6, 2-3) 1.5 (1.5, 0-3)
vs YC <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
vs GC <0.0001 <0.0001 0.0003 <0.0001 <0.0001
vs Stage I <0.0001 <0.0001 0.0032 0.0001 <0.0001
vs Stage II <0.0001 0.0001 0.5705 <0.0001 <0.0001
vs Stage III 0.0259 0.008 0.7795 0.062 0.0062
GC (n=10 ) 1 (1, 0-2) 1 (0.6, 0-1) 0 (0.3, 0-2) 1 (1, 1-1) 4 (3.9, 3-4)
YC (n=11 ) 0 (0.5, 0-1) 0 (0.2, 0-1) 0 (0, 0-0) 0 (0.5, 0-2) 4 (4, 4-4)
aData presented as median score (mean, range)




3.4.2.1 CKD Stage I 
Three cats were classified as Stage I having a serum creatinine of <1.6mg/dL, USG ≤1.035, as 
well as abnormal kidneys on gross examination. All three cats were scored as having 50-75% 
normal parenchyma remaining and this score was significantly less than that of GC cats 
(p<0.0001). In comparison with other CKD stages, Stage I cats had a significantly greater 
percent of normal parenchyma than Stages III and IV (p=0.003 and <0.0001, respectively). No 
significant difference was found between Stage I and II. Interstitial inflammation, which was 
comprised exclusively of lymphocytes, affected <25% of the section (median, 1; range, 1-2) in 
Stage I cats. Inflammation at this stage was significantly greater than YC (p=0.0041) cats but 
significantly less than Stages III and IV (p=0.0123 and <0.0001, respectively). Moreover, 
inflammatory infiltrates had a regionally extensive distribution in all cats within this group 
(Figure 3.2). Frequency of this pattern was only significantly different when Stage I cats were 
compared to YC and GC control cats (p=0.0057 and 0.0263, respectively). No difference in 











Figure 3.2  Relative frequencies of 4 different patterns of interstitial inflammation for 




Cortical and medullary scarring was nearly absent in Stage 1 cats (median 0; range 0-1), 
with one cat having a multifocal pattern of scarring occupying less than 25% of the section. 
Severity of cortical scarring within this group was significantly less than that observed in Stages 
II, III, and IV (p<0.0001 for all 3 stages). Likewise, medullary scarring was significantly less 
than other CKD stages (Stage II, p=0.0069; Stage III, p=0.0039; and Stage IV, p=0.0032). The 
pattern of scarring was found to be significantly different from all other CKD stages (versus 











Median score (1; range, 1-1) for tubular degeneration in Stage I cats was consistent with 
mild, focal to scattered cortical tubular degeneration. This change was statistically different from 
Stages III and IV (p=0.0069 and p=0.0001, respectively). Dead tubular epithelial cells were 
infrequent (mean ± standard deviation [SD], 1.4±1.7) and occurred significantly less than in GC 
cats (p=0.0007) and CKD cats in Stage II, III, and IV (p<0.0001). Tubular dilation was not 
present at this stage and this was statistically different from Stage IV (p=0.0018).  
 
Figure 3.3.  Relative frequencies of 4 different patterns of cortical scarring for each CKD 




 Glomerular lesions and mineralization of Bowman’s capsule were not present within cats 
at this stage of kidney disease. Global glomerulosclerosis was statistically more frequent in Stage 
I cats (mean ± SD, 1.4 ± 2.2) than in YC (p<0.0001) but less frequent than CKD Stages II-IV 
(Stage II, p=0.0011; Stage III and IV, p<0.0001). Global glomerulosclerosis occurred more 
frequently in GC cats compared to Stage I but the difference was not statistically significant. 
 Vascular lesions and papillary necrosis were absent in this stage while collecting duct 
mineral was present in a single cat.  No statistical significance was found when comparing these 
lesions with other groups. 
3.4.2.2 Stage II 
A total of 16 cats were classified as CKD Stage II. Similar to Stage I, Stage II cats had a median 
score for normal parenchyma that corresponded to 51-75% remaining in the examined sections 
(median, 3; range, 1-4). This was significantly less than control groups (YC and GC, p<0.0001) 
but significantly greater than later stages (Stage III, p=0.0404; Stage IV, p<0.0001). Interstitial 
inflammation affected <25% of the kidney in Stage II cats (median, 1; range, 1-3) which 
consisted mostly of lymphocytes and plasma cells, and less frequently macrophages and 
granulocytes (neutrophils or eosinophils). Severity of inflammation was significantly greater in 
Stage II compared to YC cats (p<0.0001) but significantly less than later stages (versus Stage III 
and IV, p<0.0001). Regionally extensive interstitial inflammation was the most common 
distribution in Stage II cats. Statistical significance between groups was only found when 
compared to YC cats (p=0.0125). 
Cortical (median, 1; range, 1-3) and medullary scarring (median, 1; range, 0-2) was 
significantly greater in Stage II cats than either control group (p<0.0001) or Stage I cats 
(p<0.0001). No difference in the severity of scarring was found when Stage II cats were 
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compared to Stage III cats, but scarring of the cortex was significantly less when compared to 
Stage IV cats (p=0.0001). The pattern of scarring was significantly different from YC 
(p<0.0001), Stage I (p=0.0488), and Stage IV (p=0.037). No difference in the distribution of 
scarring between Stage II and III were found. Interstitial lipid was present in a majority of cats in 
this stage, however, statistical significance was only found when comparing Stage II with control 
groups (YC, p=0.0006; GC, p=0.0048).   
 Stage II cats had a median score of 1.5 (range, 0-3) for tubular degeneration which was 
consistent with mild to moderate degeneration. Cortical tubular degeneration in Stage II was 
significantly greater than control groups (YC, p<0.0001; GC, p=0.0263). Similar to Stage I, 
Stage II cats have significantly less tubular degeneration than later stages (Stage III, p=0.0247; 
Stage IV, p<0.0001). Dead tubular epithelial cells (mean ± SD, 11.0 ± 7.0) were significantly 
more frequent than in YC and Stage I cats (p<0.0001), but were similar to the frequency 
observed in GC. Tubular epithelial cell lipid accumulation was a common finding within Stage II 
cats, similar to the other CKD cats. Nearly half of Stage II cats had cellular casts (7/16) or 
intraluminal crystals (7/16), less frequently lipid casts (6/16). Statistical significance among 
groups was not found for these variables. Tubular dilation occurred frequently (11/16), and this 
was significantly greater than either control group (YC; p=0.0003; GC, p=0.0007). Tubular 
basement membrane mineralization or coagulative necrosis was not seen at this stage.   
 Three cats in Stage II had glomerular lesions. A single cat had moderate cystic 
glomerular atrophy and another had mesangial expansion. The remaining cat had multiple 
glomerular changes including focal glomerular hypercellularity and remodeling of the 
glomerular basement membrane, consistent with a membranoproliferative glomerulonephritis 
pattern as well as focal segmental glomerulosclerosis (FSGS). Bowman’s capsule thickening 
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with or without parietal cell hypertrophy was present in a majority of cats (12/16) and this was 
significantly greater than YC cats (p=0.0002). Global glomerulosclerosis was significantly 
greater in Stage II cats (mean ± SD, 8.4 ± 6.6) compared to controls (YC, p<0.0001; GC, 
p=0.0027) and Stage I cats (p=0.0011); but significantly less than later stages (Stage III, 
p=0.0034; Stage IV, p<0.0001). 
 Vascular lesions identified in Stage II cats consisted of fibrointimal hyperplasia in 9 cats 
(Figure 3.4), hyperplastic arteriolosclerosis in 5, hyalinosis in 2, and torturous vessels in regions 
of scarring in 2. Statistical significance of the frequency of vascular lesions was not present when 
comparing Stage II cats with other groups. Lastly, the incidence of collecting duct mineral (n=8) 





















3.4.2.3 Stage III 
A total of 14 cats were classified as Stage III. There was significantly less normal renal 
parenchyma in Stage III cats, equating to approximately 25-50% of the section (median, 2; 
range, 1-4) compared to earlier stages (Stage I, p=0.003; Stage II, p=0.0404) and controls (YC 
and GC, p<0.0001). Stage III cats had significantly more normal parenchyma than Stage IV cats 
(p=0.0062). Severity of interstitial inflammation in Stage III cats was significantly different 
when compared to controls and each CKD stage. With a median score of 2 (range, 0-4), Stage III 
cats were more severely affected by inflammation than controls (YC and GC, p<0.0001) and 
early CKD stages (Stage I, p=0.0123; Stage II, p<0.0001) but was less when compared to Stage 
IV cats (p=0.0259). All cats in Stage III had interstitial lymphocytic infiltrates while half had 
plasma cells, macrophages, and granulocytes. Over half of cats in this stage had regionally 
extensive inflammation (8/14). Frequency of inflammatory patterns was only significantly 
different from controls (versus GC, p=0.0351 and YC, p=0.0027). 
Renal scarring was not as severe as inflammation in Stage III cats. Similar to Stage II 
cats, median scores for cortical and medullary scarring were 1 (range 0-4, for both variables) 
corresponding to <25% of the tissue. Scarring was significantly greater in Stage III cats than 
controls (YC and GC, p<0.0001, cortical and medullary) and Stage I (p<0.0001 and p=0.0039 
cortical and medullary, respectively). Severity of cortical scarring in Stage III cats was 
significantly less than Stage IV (p=0.008) with no difference found when compared to Stage II.  
The most frequent scarring pattern in Stage III cats was focal to striped (8/14). Statistical 
significance was found when compared to YC (p<0.0001) and Stage I (p=0.0446). Interstitial 
lipid was a common finding and occurred with significantly greater frequency than in control 
cats (YC, p=0.0003; GC, p=0.0019).   
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 The median score (2.5; range, 0-3) of tubular degeneration in Stage III cats was 
consistent with moderate to severe degeneration. These cats were affected by tubular 
degeneration significantly more than controls (YC and GC, p<0.0001) and early CKD stages 
(Stage I, p=0.0069; Stage II, p=0.0247). Although compared to Stage IV cats, a significant 
difference was not found. Dead tubular epithelial cells were significantly greater in Stage III cats 
(mean ± SD, 15.0 ± 9.7) compared to only YC controls (p<0.0001) and Stage I cats (p<0.0001). 
Cellular casts were present in 11 Stage III cats which was significantly greater than YC cats 
(p=0.0001). Tubular epithelial cell lipid accumulation was common, as was the presence of lipid 
casts (9/14) but neither lesion was significantly different from other groups. Tubular dilation was 
another frequent finding (12/14) with statistical significance when comparing Stage III with 
controls (p<0.0001). Tubular cysts and intraluminal crystals affected half of Stage III cats and 
were significantly greater than YC cats for both variables (p=0.0078).    
 Five of 14 cats in Stage III had glomerular lesions that included one or more of the 
following: FSGS, thrombotic microangiopathy, MPGN pattern, basement membrane remodeling, 
mesangial expansion, mesangiolysis, and/or glomerular hypertrophy. A single cat with focal 
thrombotic microangiopathy was a unique finding in this study (Figure 3.5); specifically, there 
was prominent glomerular endothelial hypertrophy that obscured capillary lumina and 
duplication of glomerular basement membranes in multiple glomeruli. The mean number of 
globally sclerotic glomeruli in Stage III cats was 15.7 (SD, ± 11.4) which was significantly 
different from all other groups (YC, GC, Stage I p<0.0001; Stage II, p=0.0034; Stage IV, 
p=0.0117). Over half of the Stage III cats had glomeruli with thickened Bowman’s capsules and 














Vascular lesions identified in Stage III cats consisted of fibrointimal hyperplasia (9/14), 
hyperplastic arteriolosclerosis (8/14), and a single case each of hyalinosis and torturous vessels 
in regions of scarring. The frequency of hyperplastic arteriolosclerosis was significantly greater 
in Stage III cats when compared to YC cats (p=0.0029). Lastly, the frequency of collecting duct 
mineral (6/14) or papillary necrosis (1/14) was not significantly different between Stage III cats 
and any other group. 
3.4.2.4 Stage IV 
A total of 13 cats were classified as Stage IV. Normal renal parenchyma was significantly less in 
Stage IV cats than all other groups (median, 1.5; range, 0-3; versus YC, GC, Stage I, Stage II, 
p<0.0001; Stage III, p=0.0062). Interstitial inflammation was the most severe in Stage IV cats 
affecting 50-75% of the section examined (median, 3; range, 1-4) which was significantly 
different from controls (YC and GC, p<0.0001) and other CKD stages (Stage I, p<0.0001; Stage 
II, p<0.0001; Stage III, p=0.0259). Populations of inflammatory cells in a majority of cases were 
 
Figure 3.5.  Thrombotic microangiopathy, glomerulus, kidney, cat.  Endothelial 
cells are swollen and frequently obscure the capillary lumen (inset). Periodic acid-




composed of lymphocytes (13/13) and plasma cells (9/13) with macrophages and / or 
granulocytes being present in 5 cats. Pattern of inflammation was variable.  Statistically 
significant differences between the frequency of inflammatory patterns was found when 
comparing Stage IV to controls (YC, p<0.0001; GC, p=0.0028) but not with other CKD stages.   
The median score for cortical scarring was greater than that in the medulla for Stage IV 
cats (cortical median, 2; range, 1-4; medullary median, 1; range, 0-4). Cortical scarring was 
significantly greater in this late stage compared to controls (YC, p<0.0001; GC, p<0.0001) and 
all CKD stages (Stage I, p<0.0001; Stage II, p=0.0001; Stage III, p=0.008; Figure 3.6). 
Medullary scarring was only significantly different from controls (YC, p<0.0001; GC, p=0.0003) 
and Stage I cats (p=0.0032). The majority of Stage IV cats were affected by regionally extensive 
scarring (7/13). Frequency of scarring patterns was significantly different when Stage IV cats 
were compared to controls (YC, p<0.0001; GC, p=0.0011) and early stages of CKD (Stage I, 
p=0.0016; Stage II, p=0.037). Interstitial lipid was present in all Stage IV cats with statistically 
significant difference in incidence when compared to controls (YC, p<0.0001; GC, p=0.0005) 





















Tubular degeneration in Stage IV cats was marked affecting entire nephrons (median, 3; 
range, 2-3). Percent of tissue affected was significantly greater in Stage IV CKD than controls 
(YC and GC, p<0.0001) and earlier stages of CKD (Stage I, p=0.0001; Stage II, p<0.0001). 
Similarly mean individual dead tubular epithelial cells were significantly greater than controls 
(mean ± SD, 19.9 ± 10.8; YC, p<0.0001; GC, p=0.001) and early CKD stages (Stage I, 





Figure 3.6  Scarring in chronic kidney disease, kidney, cat.  Figure 3.6.1 Cortical scarring 
score of ‘1’ with minimal tubular atrophy and interstitial expansion by increased matrix. 
Masson’s trichrome stain.  Figure 3.6.2 Scarring score of ‘2’ with increased interstitial fibrosis, 
periglomerular fibrosis, and tubular atrophy.  Masson’s trichrome stain.  Figure 3.6.3 Score of 
‘3’ with at least 50% of the tissue affected by interstitial fibrosis, tubular atrophy, and 
glomerulosclerosis (not present in image).  Masson’s trichrome stain.  Figure 3.6.4 Score of ‘4’ 
with a majority of the cortical parenchyma replaced by fibrosis, tubular atrophy and loss; and 
glomerulosclerosis.  Masson’s trichrome stain. 
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Stage IV cats. However, lipid in tubular epithelium was common among all groups.  Cellular 
casts were more frequent in Stage IV compared to YC cats (11/13, p<0.0001). Tubular dilation 
(13/13) and cysts (11/13) occurred more frequently in Stage IV cats than controls (YC and GC, 
p<0.0001). Stage IV cats were more likely to have tubular dilation than Stage I cats (p=0.0018) 
and more likely to have tubular cysts than Stage II cats (p=0.008). Intraluminal crystals were a 
common finding (9/13) but not statistically different from other groups. Likewise no significant 
difference was found in prevalence of tubular basement membrane mineralization (3/13) or 
tubular coagulative necrosis (0/13) when Stage IV cats were compared with other groups. 
The majority of Stage IV cats in this study (10/13) had some degree of glomerular lesion.  
Lesions affecting glomeruli in this stage included one or more of the following:  FSGS, 
glomerular hypertrophy, mesangial expansion, endothelial hypertrophy, MPGN pattern, and 
cystic glomerular hypertrophy. The prevalence of glomerular lesions at this stage was 
significantly more than that seen in controls (YC, p=0.0006; GC, p=0.002) and Stage II 
(p=0.009). Mean global glomerulosclerosis was greater in Stage IV than any other group (mean 
± SD, 25.7 ± 13.8; versus YC, GC, Stage I, Stage II p<0.0001; Stage III, p=0.0117).  
Mineralization (2/13) and thickening of Bowman’s capsule with or without parietal cell 
hypertrophy (8/13) were present in Stage IV cats.   
Stage IV kidneys frequently contained vascular fibrointimal hyperplasia (8/13) but 
infrequently were affected by hyperplastic arteriolosclerosis (3/13). A total of 5 Stage IV cats 
had vascular lesions which consisted of a single case of tunica media mineralization, hyalinosis, 
fibrinoid necrotizing arteritis, endothelial swelling, and diffuse torturous vasculature. The cat 
with mineralization of the tunica media had concurrent Bowman’s capsule and tubular basement 
membrane mineralization. Prevalence of vasculature lesions was not significantly different in 
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Stage IV cats from controls or other stages. Finally, frequency of collecting duct mineral (7/13) 
or papillary necrosis (2/13) was not significantly different between Stage IV cats and any other 
group. 
3.4.3 Clinicopathologic Data 
Clinicopathologic data for each group is summarized in Table 2. Analysis of the relationship 
between histologic lesions and serum creatinine did not reveal any major differences from what 
was observed when analysis of the relationship between histologic variables and individual IRIS 
stages was performed (data not shown). A total of 33 cats out of 46 included in this study had 
UPC measurements available for analysis. Nine CKD cats (Stage III: 1 cat, Stage IV: 8 cats) 
were proteinuric (UPC >0.4). Eight CKD cats (Stage II: 2 cat; Stage III: 5 cats, Stage IV: 1 cat) 
were classified as borderline proteinuric (UPC 0.2-0.4) and 16 CKD cats were non-proteinuric 
(Stage I, n=1; Stage II, n=11; Stage III, n=1; Stage IV, n=3). All control cats (YC and GC) were 
non-proteinuric. Non-proteinuric cats (n=37) were more likely to have a greater percent of 
normal parenchyma than either borderline proteinuric cats (p=0.0014) or proteinuric cats 
(p<0.0001). Interstitial inflammation and cortical scarring were significantly greater in 
proteinuric cats than borderline (p=0.0402 and p=0.0052, respectively) and non-proteinuric cats 
(p≤0.0001). Medullary scarring in contrast was only significantly different between non-
proteinuric and borderline proteinuric cats (p=0.0006). Inflammatory constituents were not 
significantly different between groups. Tubular degeneration was significantly less frequent in all 
non-proteinuric cats when compared to borderline (p=0.0003) and proteinuric (p<0.0001) cats. 
Frequency of cellular and lipid casts were significantly less in non-proteinuric cats than 
borderline (p=0.028) and proteinuric cats (p=0.0162 and p=0.05, respectively). The presence of 
lipid vacuoles in normal tubules was significantly greater in non-proteinuric cats than borderline 
59 
 
(p=0.0014) and proteinuric cats (p<0.001). Incidence of tubular crystals in non-proteinuric cats 
was significantly less than either borderline (p=0.031) or proteinuric cats (p=0.0046). Tubular 
dilation and cysts were significantly less likely to occur in non-proteinuric cats than borderline 
cats (p=0.017 and p=0.0299, respectively), however, cysts were more likely to occur in 
proteinuric cats when compared to non-proteinuric cats (p=0.0029). Dead tubular epithelial cells 
were significantly greater in borderline proteinuric (p=0.0009) and proteinuric cats (p=0.0081) 
when compared to non-proteinuric cats. 
 Glomerular lesions occurred more frequently in proteinuric cats than both non-proteinuric 
cats (p=0.0004) and borderline proteinuric cats (p=0.018). In contrast global glomerulosclerosis 
was only significantly different when comparing non-proteinuric cats to proteinuric cats 
(p=0.007). Bowman’s capsule mineralization was significantly worse in borderline proteinuric 
cats compared to non-proteinuric cats (p<0.0001; mineral was not seen in all groups, therefore, 
significance could not be determined). No significance difference in the occurrence of vascular 
lesion was found between non-proteinuric, proteinuric and borderline proteinuric cats.  
 A total of 33/46 CKD cats had blood pressure data available for analysis; Stage I (n=1), 
Stage II (n=12), Stage III (n=9), and Stage IV (n=11). All 10 GC cats had available systolic 
blood pressures and were normotensive. Conversely, no information in regards to blood pressure 
was available for YC cats. The single Stage I cat with available blood pressure was hypertensive. 
Half of Stage II (n=6), 2 Stage III, and 4 Stage IV cats with available blood pressure data were 
hypertensive. Hypertension was more likely to occur in cats with CKD than GC cats (p=0.03). 
Presence of hyperplastic arteriolosclerosis, fibrointimal hyperplasia, or other vascular lesions 




3.5 Discussion   
While progress has been made in better categorizing stages of feline CKD and the 
associated prognosis and treatment recommendations, a great deal is still unknown about the 
etiopathogenesis of such a common disease.17 Clinicopathologic data is useful for diagnosing, 
staging, and prognosticating but gives few clues about the distribution and pattern of injury 
within the kidney. Therefore, it is difficult to determine which stages are characterized by 
irreversible lesions and at which stage therapeutic interventions should be targeted. In an attempt 
to bridge clinical parameters with renal pathology, reversible and irreversible histologic lesions 
affecting all renal compartments were identified for each stage of CKD. This study showed that 
reversible lesions were present throughout the stages of CKD while irreversible lesions were 
more prevalent in later stages than early stages of CKD.   
Histologic variables that were significantly different among stages affected the 
interstitial, tubular, and glomerular compartments. Overall, earlier stages of CKD (i.e. Stages I 
and II) retained a greater proportion of normal parenchyma in comparison to later stages (i.e. 
Stages III and IV). Within the interstitial compartment the severity of inflammation was similar 
in earlier stages and significantly less than later stages. Lymphocytes were the most common 
constituent of inflammation at any stage and a regionally extensive pattern was most frequent. 
Lipid within the interstitium was frequently associated with interstitial inflammation and scarring 
while edema was rare. Cortical scarring was prevalent in the final stages of CKD (Stage IV), but 
was mild in cats in Stages II and III. Tubular degeneration was significantly greater in later 
stages when compared to earlier stages, although the degree of degeneration was similar between 
individual later stages (i.e. Stages III and IV). Tubular lipid was a frequent finding in normal and 
atrophic tubules.  Single epithelial cell necrosis was significantly less in the earliest stage of 
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disease (Stage I) than all other stages, however, coagulative necrosis was rare. 
Glomerulosclerosis progressively worsened with CKD stage while other glomerular lesions were 
uncommon. Vascular lesions did not differ among IRIS stages. 
Normal parenchyma unaffected by degeneration, atrophy, inflammation, or fibrosis was 
significantly less in later stages of CKD (i.e. Stage III and IV) compared to earlier stage (Stages I 
and II) but similar between Stages I and II. Interestingly, as little as 25-50% of the parenchyma 
was affected in the earlier stages of CKD implying that even mild degree of lesions could have 
functional significance.  This is in contrast to the dogma that at least 75% of functional mass 
must be lost before clinical evidence of renal disease is evident.18-21 The determination of the 
functional consequence of histologic lesions involving only ≤50% of the renal tissue was based 
on serum creatinine levels as an estimate of renal function, as is commonly used in clinical 
practice.  Other functional tests such as glomerular filtration rates which have been demonstrated 
to decline with 75% or greater surgical reduction in renal mass in cats were not measured in this 
study.21-24 Reasons for this contradiction may include uncertainty of the relationship between 
histologic assessment of normal parenchyma and functional renal mass and potential variation in 
whether the most or least severe renal lesions were sampled for histopathology in the 11/46 cases 
that were collected retrospectively in a unilateral manner. 
Percent tubular degeneration was significantly greater in later stages than earlier stages of 
disease, but was not different between controls and Stage I.  This could be a result of small 
sample size for Stage I. In fact the only histologic lesions significantly different between 
geriatric controls and Stage I CKD cats were percent normal parenchyma and tubular epithelial 
single cell necrosis with the latter being greater in geriatric controls. When comparing all CKD 
stages there was an obvious upward trend of tubular epithelial single cell necrosis with each 
62 
 
stage although statistical significance was not reached between stages. Lastly, the authors 
acknowledge that the methods used would not differentiate single cell necrosis and include 
apoptosis.  
Interstitial fibrosis and scarring, confirmed by Masson’s trichrome stain, was statistically 
greater in Stage IV compared to all other stages. Cats in Stage IV were most likely to have 25-
50% of their kidneys affected by scarring in comparison to ≤25% scarring in other stages. 
Interstitial fibrosis did not increase significantly between cats in IRIS Stage II and III. This is in 
contrast to a previous study (which did not evaluate tissues stained with trichrome) where 
interstitial fibrosis was the lesion that best correlated with severity of azotemia.7  This suggests 
that additional pathologic processes other than fibrosis are involved in disease progression, and 
implies that initiation of any potential anti-fibrotic therapies in CKD cats should occur prior to 
Stage IV when irreversible fibrosis is most severe.  
While mean percentage of tissue affected by interstitial inflammation increased between 
stages II-IV, histologic scores for inflammation were typically greater than scarring scores for 
each stage. This would be compatible with inflammation preceding and inducing fibrosis.15 
However, patterns of scarring did not parallel that of interstitial inflammation and a significant 
progression in scarring patterns from focal to regional to diffuse with increasing IRIS stage was 
not found. This suggests that instigators of fibrosis other than inflammation may be players in the 
progression of CKD and should be identified and evaluated as potential therapeutic targets. 
Glomerulonephropathies, with the exception of FSGS, were infrequently diagnosed by 
light microscopy (4/46). Due to the retrospective nature of this study tissues were not available 
for ultrastructural evaluation. However our results were similar to previously published work on 
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feline renal disease where glomerular disease was uncommon with a reported prevalence of 8-
15%.2, 5, 6, 25 In the present study the most common glomerular changes were global 
glomerulosclerosis and FSGS. Global glomerulosclerosis was the only histologic variable in this 
study that precipitously increased with IRIS stage progression. Interestingly, glomerulosclerosis 
was more severe in non-azotemic geriatric cats than Stage I CKD cats. This suggests that 
although global glomerulosclerosis appears to be a feature of aging, it can be considered 
pathologic in certain scenarios.26 Additional studies on non-azotemic geriatric cats are needed to 
better characterize normal renal aging changes. 
Focal segmental glomerulosclerosis is a poorly characterized entity in veterinary 
medicine.27, 28 Histologic features are one or more glomeruli with segmental consolidation of 
capillary tufts with replacement by increased extracellular matrix, cellularity, or both.29, 30 
Clinically, proteinuria is a hallmark of FSGS and typically is accompanied by variable degrees of 
hypoalbuminemia, hypercholesterolemia, and edema (nephrotic syndrome) in human patients.29 
Etiologies for FSGS are classified as either primary (idiopathic or genetic) or secondary 
(adaptive) the latter encompasses drug-induced or viral-associated causes.29, 30  In humans, 
distinct histologic variants of FSGS have been identified, based on location and character of the 
lesion within the glomerular tuft, and have been found to relate to specific therapeutic responses 
and prognostic outcomes. For example, the variant perihilar FSGS is defined by sclerosis at the 
vascular pole and often seen in secondary, adaptive FSGS.  Individuals with perihilar variant of 
FSGS typically have nephrotic syndrome less frequently with a milder degree of proteinuria than 
other variants.30  Aging, advanced renal disease and obesity are three examples of conditions that 
are associated with adaptive FSGS.29, 30 
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In the current study, 8 cats with CKD had histologic evidence of FSGS.  Urinalysis and 
UPC measurements were available for 6 of the 8 cats. Although none of the cats suffered from 
nephrotic syndrome, 5/6 were proteinuric with only 2/6 within nephrotic range (UPC > 2.0). A 
single cat was hypoalbuminemic but proteinuric status was not available for this cat. However, 
hypoalbuminemia in this cat was most likely due to pleural effusion from severe mediastinitis 
secondary to complications from an esophageal feeding tube rather than glomerular disease. 
While Leishmania infection in dogs has been associated with chronic glomerulosclerosis, other 
primary or secondary etiologies for FSGS in veterinary medicine have not been reported.31 Viral 
infections (e.g. parvovirus or feline immunodeficiency virus) were not suspected clinically. None 
of the cats in the current study were treated with any FSGS-associated drugs.  While these 8 cats 
may have had primary FSGS, that is typically a diagnosis of exclusion. A more plausible 
explanation would be that these lesions were secondary to adaptive changes due to the loss of 
functional renal mass in these cats. Loss of functional glomeruli leads to hyperfiltration of the 
remaining glomeruli which can result in podocyte injury and eventually sclerosis. In support of 
this theory, perihilar pattern of segmental sclerosis was identified in 4 of the 8 cats with FSGS in 
this study. Based on histopathology and clinicopathologic data it seems most likely that FSGS in 
these 8 cats were likely secondary, or adaptive, to loss of renal mass. 
In the present study, proteinuria was an uncommon finding and typically present in later 
stages of disease. Despite the infrequency of proteinuria in CKD cats, an association with 
increased severity of tubular degeneration, inflammation, fibrosis, tubular epithelial single cell 
necrosis and decreased normal parenchyma was detected. Similarly, positive correlations 
between severity of proteinuria and tubular epithelial injury, interstitial inflammation and fibrosis 
have been found in humans.32  Protein exposure to tubular epithelial cells perpetuates renal 
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injury by direct damage to these cells or indirectly through production of proinflammatory and 
profibrotic cytokines. 32-34 
Cats with glomerular lesions had an average UPC greater (1.3 ± 1.8) than those cats 
without glomerular lesions (0.2 ± 0.1), however, a UPC > 2 was only present in 3 cats. These 
were late stage (Stage III: n=1, Stage IV: n=2) and glomerular lesions were marked (e.g. MPGN 
pattern and TMA). A UPC > 2 typically indicates glomerular disease while tubular reabsorption 
defects are suspected if < 2.35 These data suggest that proteinuria in study cats is unlikely a result 
of primary glomerular disease in a majority of cases and is more likely tubular in origin. In this 
study, proteinuria was more common in late stage cats implying that it is a consequence rather 
than an initiator of disease.  
Mineralization of Bowman’s capsule and tubular basement membranes was more 
frequent in cats with more severe renal disease (i.e. Stages III and IV) than those with milder 
disease (Stages I and II). While calcium-phosphorus products (CPP) were not evaluated in the 
current study, mineralization may be the result of an increased CPP secondary to late--stage renal 
disease.36, 37  
A novel glomerular lesion identified in this report was thrombotic microangiopathy 
(TMA). This cat presented for acute onset of ataxia and blindness. Systolic blood pressure was 
190 mm Hg at presentation with severe proteinuria (UPC 4.8) and a creatinine of 3.2 mg/dL. 
Histologically, scattered glomeruli had endothelial swelling with occlusion of capillary lumina 
which is a characteristic feature of the TMA variant glomerular endotheliosis.38, 39 Endotheliosis 
diminishes filtration and thus decreases overall glomerular filtration rate (GFR) in affected 
individuals.38 Endotheliosis is often seen in women due to pre-eclampsia with clinical 
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hypertension and proteinuria. Although, unrelated to pregnancy in the cat reported here, 
confirmed hypertension may have resulted in endothelial injury with endotheliosis. The 
relationship of this to feline CKD is unknown. 
Vascular lesions other than fibrointimal hyperplasia and hyperplastic arteriolosclerosis 
were uncommon. Fibrointimal hyperplasia appeared as segmental to circumferential thickening 
of the tunica intima accompanied by a discontinuous internal elastic lamina.  It was present in 
over half of all CKD cats as well as in young normal cats, and did not differ among stages of 
CKD.  Fibrointimal hyperplasia has been associated with hypertension but is indistinguishable 
from similar lesions in aging, normotensive human patients.40, 41 Ultimately, vascular lesions 
associated with hypertension may lead to glomerular damage, sclerosis, tubular atrophy, and 
interstitial fibrosis.42 In the present study, however, hypertensive cats were not more likely to be 
affected by fibrointimal hyperplasia than normotensive cats. In a study evaluating lesions in the 
aging feline kidney, vascular lesions were infrequent (6/600 cats), although lesion detection may 
have been limited in that study by the absence of histochemical stains.6  In a recent study 
assessing renal histologic lesions in diabetic cats, vascular lesions were infrequent, with only 4 
cats affected by arterial hypertrophy and a single cat with vascular thickening and splitting.4 
Lesions were not significantly different between those cats with or without diabetes mellitus.4 
Lastly, in the present study fibrointimal hyperplasia was prevalent in young, non-azotemic cats 
(6/11). From these data, the relationship of this vascular lesion to feline kidney disease is 
uncertain.  
Hyperplastic arteriolosclerosis, a feature of systemic hypertension thought to be due to 
microvascular injury, was found in 48% of normotensive cats with CKD. This is in contrast to a 
previous report of 3% in normotensive CKD cats.7 The reason for this discrepancy is not clear, 
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but may indicate that systemic blood pressure does not adequately represent local renal 
hemodynamics in cats. For example, in a previous study, cats with CKD had significantly higher 
renal vascular resistance than cats without CKD, despite no difference in systemic blood pressure 
between groups, as well as no correlation between systemic blood pressure and renal arterial 
resistance indices.43 In contrast, in humans, indices of vascular resistance (RI) are associated 
with the severity and progression of CKD and RI correlates with systemic blood pressure. The 
reason for the difference between species is unclear but increased RI may be a more accurate 
measurement of local renal hemodynamics in cats.  
Irregularly-sized lipid vacuoles were frequent within tubular epithelium and free within 
the interstitium of CKD cats in this study. Interstitial lipid is thought to originate from tubular 
lipid after rupture of basement membranes and cell lysis.44 The role of tubular lipidosis in feline 
CKD has not been determined. Given that many different lipids have identical histologic 
appearances, it is unclear whether the larger lipid vacuoles and lipid casts are simply due to 
coalescence of smaller vacuoles from normal feline tubules or if they are composed of different 
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CHAPTER 4: RELATIONSHIP BETWEEN SERUM CREATININE, SERUM GASTRIN, 
CALCIUM-PHOSPHORUS PRODUCT AND UREMIC GASTROPATHY IN CATS WITH 
CHRONIC KIDNEY DISEASE 
4.1 Chapter Summary 
Chronic kidney disease (CKD) in cats is associated with gastrointestinal signs commonly 
attributed to uremic gastropathy. Consequently, patients are often treated with antacids and 
gastrointestinal protectants. This therapeutic regime is based on documented gastric lesions in 
uremic humans and dogs; however the incidence of uremic gastropathy in cats is unknown.  The 
objective of this study was to determine and the prevalence and characterize gastric lesions in 
cats with CKD.  In addition, histologic lesions were compared with serum creatinine, calcium-
phosphorus product (CPP) and serum gastrin concentrations.  A total of 37 CKD cats and 12 
non-azotemic control cats were evaluated.  Gastric ulceration, hemorrhage, edema, and vascular 
injury, were not observed in cats with CKD. The most significant gastric lesions in CKD cats 
were fibrosis and mineralization. Sixteen CKD cats (43%) had evidence of gastric fibrosis of 
varying severity and 14 CKD cats (38%) had gastric mineralization. Cats with CKD were more 
likely to have gastric fibrosis and mineralization than non-azotemic controls (p=0.005 and 
p=0.021, respectively). Only cats with moderate and severe azotemia had gastric mineralization. 
CPP was correlated to disease severity; severely azotemic CKD cats had significantly greater 
CPP when compared to non-azotemic controls, and to mildly and moderately azotemic cats 
(p<0.05). Gastrin concentrations were significantly greater in CKD cats when compared to non-








Chronic kidney disease (CKD) is a common clinical problem that affects a significant proportion 
of aged cats.1 Progression of CKD typically results in uremia, a syndrome that manifests 
clinically as a variety of signs, including weight loss, vomiting, inappetance, and anorexia.1-4 
These clinical signs are frequently ascribed to uremic gastritis, a condition attributed to the 
presence of uremic toxins and gastric hyperacidity secondary to hypergastrinemia.5 However 
there are significant gaps in our understanding of the prevalence and pathogenesis of feline 
uremic gastrointestinal disease.  
Uremic gastritis was first described in 1934 from autopsies in 135 uremic human 
patients; lesions varied from mild edema to hemorrhage, ulceration,  and necrosis.6 Although 
complications of uremia such as gastritis, ulceration, and hemorrhage are common in humans,7 
they appear to be less common and less severe in dogs.8 In 1979 Cheville described vascular 
injury, calcification, mucosal edema, and necrosis in the stomachs of a small group of uremic 
dogs with renal amyloidosis and pyelonephritis.9 In a more recent study, mucosal necrosis was 
found to occur less frequently, while mineralization, edema and vascular injury were frequently 
present in dogs with renal disease.8 The prevalence of uremic gastritis has not been 
systematically evaluated in cats. A report of 70 cats with acute renal toxicity due to 
contamination of food with melamine and cyanuric acid indicated that a small percentage of 
animals had gastric mineralization, but ulceration was not observed.10 In addition, an 
experimental study of Easter lily poisoning in cats reported an absence of gastric lesions in 10 
cats that were examined by necropsy.11 Finally, in a case series and literature review of gastric 
ulceration in cats, CKD was not found to be an underlying cause.12  
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Cats with CKD have been shown to have elevated concentrations of gastrin that increase 
with the severity of renal failure,5 but the relationship between gastrin, gastric acid secretion, and 
gastric pathology has not been investigated. Gastrin is secreted by G cells in the gastric antrum 
and stimulates the secretion of gastric acid by the parietal cells. The presence of gastric acid 
results in negative feedback to decrease the secretion of gastrin. In humans and dogs, gastrin is 
excreted by the kidneys, and it is hypothesized that as renal function declines, hypergastrinemia 
develops, resulting in gastric hyperacidity.5 Cats that have gastrin-secreting tumors with levels of 
hypergastrinemia similar to those found in cats with CKD have significant gastric pathology; 
however no study has shown this to be the case in cats with CKD.12  Even in humans, the 
development of hyperacidity in association with CKD appears to be inconsistent, and may be 
related to the presence of Helicobacter spp. infection.13 Thus there is very little available 
evidence on which to base recommendations for the use of acid-reducing medications such as H2 
blockers, proton pump inhibitors or sucralfate in cats with uremia.1-4 The aims of this study were 
to evaluate the type and prevalence of histopathologic lesions in the stomach of cats with CKD, 
and to determine whether degree of azotemia, calcium-phosphorus products and serum gastrin 
concentrations are correlated with gastric pathology. A better understand of gastric pathology in 
CKD cats will facilitate the refinement of medical management strategies for gastrointestinal 
symptoms.  
4.3 Material and Methods 
4.3.1 Animals 
Feline CKD patients necropsied at the Colorado State University Veterinary Teaching Hospital 
(CSU-VTH) between years 2009-2012 were prospectively included in the study. Inclusion 
criteria included historical and clinicopathological findings consistent with CKD, a complete 
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necropsy with evaluation of all major organs, and a serum biochemistry profile and urinalysis 
performed within 2 weeks of euthanasia or death. All owners signed the CSU-VTH consent form 
for euthanasia (when applicable) and educational necropsy; no cats were euthanized for the 
purpose of this study. Exclusion criteria included concurrent primary gastrointestinal disease, 
such as neoplasia, administration of non-steroidal anti-inflammatory drugs or glucocorticoids 
within two weeks prior to euthanasia and ureteral obstruction identified as a post-renal cause of 
azotemia. CKD cats were defined as those with creatinine over 1.6 mg/dL, a urine specific 
gravity (USG) of less than 1.035, and evidence of changes consistent with CKD on renal 
histopathology. Cats were grouped based on severity of azotemia as follows: mild (1.6-2.8 
mg/dL), moderate (2.9-5.0 mg/dL), and severe (>5.0 mg/dL). Although this grouping is in 
accordance with IRIS Staging system,2 staging could not officially be performed as two serum 
creatinine measurements during a clinically stable period were not available for all cats.  
Labwork performed when marked dehydration or clinical decompensation was noted in the 
medical record was not included in analysis. Information regarding administration of antacid 
medications and phosphate binders was recorded. Non-azotemic control cats were young, 
apparently healthy cats in good body condition and free of reported gastrointestinal disease that 
were euthanized at a local humane society, according to humane society guidelines and 
protocols. Study samples were obtained from these cats after euthanasia, and no cats were 
euthanized for the purpose of this study.  Age was estimated by humane society staff based on 
surrender history and/or dental assessment. Non-azotemic status was defined as cats with urine 





4.3.2 Clinicopathologic Data 
For the CKD cats, serum creatinine concentration, serum total calcium concentration, serum 
phosphorus concentration and USG values measured within 2 weeks of euthanasia were obtained 
from the medical record. Calcium x phosphorus product (CPP) was calculated as serum total 
calcium concentration multiplied by serum phosphorus concentration and expressed in mg2/dL2. 
For the non-azotemic control cats, serum creatinine, total calcium and phosphorus, serum gastrin, 
and USG were obtained on samples obtained immediately post-mortem via cardiac venipuncture 
and urinary bladder cystocentesis.  
4.3.3 Gastrin Assay 
For measurement of serum gastrin concentrations, serum left over from biochemical analysis was 
collected, stored at -80oC, and shipped to Michigan State University for analysis. Circulating 
concentrations of gastrin were measured with a commercially available radioimmunoassay kit, 
with assay procedures performed according to the manufacturer’s protocol (Gastrin [125I] 
Radioimmunoassay Kit, MP Biomedicals, Diagnostics Division, Orangeburg, NY 10692-1294). 
Synthetic human gastrin17-I standards were used to make the displacement curve, with the 
highest standard of 1000 ng/L. The manufacturer reported the following percent cross reactivity 
with related compounds: gastrin 17-I (100%), gastrin 17-II (77%), gastrin 34-I (42%), gastrin 5-
17 (54%), cholecystokinin-PZ (<0.1%), and cholecystokinin-8 (10.9%). The manufacturer-
reported sensitivity of detection was 3 ng/L. For intra-assay repeatability (10 replicates), the % 
coefficient of variation was 8.6% for a feline sample with a gastrin concentration of 45 ng/L. For 
inter-assay repeatability (10 replicates), the % coefficient of variation was 9.2% for a feline 
sample with a concentration of 54 ng/L. Three feline samples with higher concentrations of 
gastrin (461, 145, 124 ng/L) were diluted with 0 standard at rates of 1:2, 1:4, and 1:8. The 
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average recovery (observed/expected) at these dilutions was 121%, 130%, and 138%, 
respectively. 
4.3.4 Gross and Histopathologic Evaluation 
Complete necropsies were performed on all animals with evaluation of all major organs. 
Specifically, the stomach was incised along the lesser curvature from cardia to pylorus and 
grossly evaluated for the presence of edema, hemorrhage, ulceration or other visible 
abnormalities. Kidneys were cut longitudinally along the long axis (cranial to caudal pole).  
4.3.4.1 Gastric Histopathology 
Three full thickness cross-sections from five anatomic locations of the stomach (cardia, fundus, 
body, antrum, and pylorus) were sampled in a routine manner. Tissues were preserved in 10% 
neutral buffered formalin, paraffin embedded, and sectioned at 5µm. All sections were stained 
with standard hematoxylin and eosin histochemical stain and evaluated independently by 2 
pathologist (SM and CD), blinded to clinical data. For final lesion score, discrepancies between 
the pathologists were resolved by joint review of tissues. Lesion description and scoring rationale 
are outlined in Table 4.1. All sections were systematically reviewed for the presence or absence 
of histologic changes consistent with uremic gastropathy as observed in dogs (i.e. amyloid, 
edema, vascular fibrinoid change, fibrosis and mineralization).8,9 An overall qualitative score 
was given for mineralization in all gastric sections highlighted by Von Kossa stain. Evaluation of 
fibrosis utilizing Masson’s trichrome was restricted to sections from the gastric body, and a 
semi-quantitative scoring scheme for fibrosis was adapted from WSAVA gastrointestinal 
evaluation guidelines.14,15 Finally, sections from the gastric body were evaluated for the presence 
and character of superficial mucosal inflammation, ulceration and/or erosion, and presence of 
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lamina proprial lymphoid nodules. Overall inflammatory infiltrates in the body, if present, were 
graded using a modification of previously published guidelines and visual scoring scale.14,16 
4.3.4.2 Renal Histopathology 
Renal sections from CKD and control cats were examined independently by two pathologists 
blinded to clinical and gastric findings for confirmation of CKD and lesion scoring. Descriptions 
of lesion scoring are outlined in Table 4.1.  For final lesion score, discrepancies between the 
pathologists were resolved by joint review of tissues. Semi-quantitative analysis for the presence 
of amyloid (Congo red) and fibrosis (Masson’s trichrome) in the kidney were given a score from 
0-3 by each pathologist. 
4.3.5 Statistical Analysis 
Serum creatinine concentration, USG, CPP, serum gastrin concentration and gastric lesion scores 
were compared between non-azotemic control cats and CKD cats with mild, moderate, or severe 
azotemia using one-way analysis of variance (ANOVA) and Bonferroni’s multiple comparison 
post hoc test with Prism software (Prism 5, GraphPad, La Jolla, CA). Scoring consensus between 
the two pathologists for each category was evaluated by Cohen’s kappa coefficient with SAS 
software (SAS 9.1.3, SAS Institute Inc., Cary, NC). Comparison between individual groups 
(presence of gastric lesion scores in normal versus CKD cats, the CPP of CKD cats with gastric 
mineralization versus those without gastric mineralization, and cats receiving phosphate binders 
or antacids versus those who were not) was performed using a Mann-Whitney test with Prism 













Fifty-nine cats with CKD were necropsied during this time period; 37 met the inclusion criteria 
for the study. Twenty-two were excluded for the following reasons: routine gastric samples not 
obtained (7), no laboratory testing near the time of euthanasia or marked 
dehydration/decompensation at time laboratory data was collected (7), intestinal neoplasia (6), 
autolysis (1) and FIV positive status (1). In total, 9 mildly azotemic cats, 9 moderately azotemic 
cats, 19 severely azotemic cats, and 12 non-azotemic controls were included in the study. 
The mean age for CKD cats was 13.8 years, ranging from 5 to 21 years of age. There 
were 24 spayed females and 13 castrated male cats. All but two CKD cats were euthanized due 
to poor or declining quality of life. The remaining two cats died at home, and were kept cold and 
submitted for necropsy within 12 hours of death. Five of the CKD cats included in this study 
were receiving famotidine antacid therapy at the time of death (mild azotemia: 2 cats; moderate 
azotemia: 1 cat; severe azotemia 2 cats), while 9 were receiving oral aluminum hydroxide 
phosphate binder therapy (mild azotemia: 1 cat; moderate azotemia: 1 cat; severe azotemia 7 
cats). Average estimated age of control cats was 2.7 years (range 0.8-4 years of age). There were 
2 male intact and 1 female intact cats; 3 neutered male cats and 6 spayed female control cats. 
Control cats had no known history of renal disease, gastrointestinal disease or medication 
administration.  
4.4.2 Clinicopathological Data 
Serum creatinine, USG, CPP and gastrin results for all groups are summarized in Table 4.2. As 
expected, when analyzed with a one-way ANOVA, serum creatinine values were significantly 
higher in severely azotemic CKD cats compared to mild and moderately azotemic groups 
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(p<0.05), while non-azotemic control serum creatinine values were significantly lower than those 
of moderately and severely azotemic CKD cats (p<0.05). Urine specific gravity in non-azotemic 
control cats was significant greater than USG in each CKD group (p<0.05) when analyzed using 
a one-way ANOVA. Calcium x phosphorus product was correlated to disease severity; when 
analyzed using a one-way ANOVA severely azotemic CKD cats had significantly greater CPP 
when compared to non-azotemic controls, mildly azotemic cats and moderately azotemic cats 
(p<0.05) (Figure 4.1). No change in statistical significance was noted when cats that had been 
administered phosphate binders were removed from analysis. The CPP of severely azotemic cats 
receiving phosphate binders was not significantly different from severely azotemic cats not 
receiving phosphate binders when compared with a Mann Whitney test. Although cats with 
gastric mineralization had higher CPP relative to cats without mineralization (114.6 mg2/dL2 and 
82.5 mg2/dL2 respectively) this difference was not statistically significant (p=0.058).  
Circulating serum gastrin concentrations in cats with CKD were significantly higher than 
serum gastrin concentrations in control cats (p=0.003) when compared using a Mann Whitney 
test. When all groups were compared using a one-way ANOVA, cats with severe azotemia had 
significantly higher serum gastrin concentrations than the control group (p<0.05, Figure 4.2). No 
change in statistical significance was noted when cats that had been administered antacids were 
removed from analysis. The median serum gastrin concentration of azotemic cats receiving 
antacids was not significantly different from the median serum gastrin concentration of those 












Figure 4.1 Calcium x phosphorus product (CPP) is correlated to disease severity. 
Severely azotemic CKD cats had significantly greater CPP when compared to 
non-azotemic controls (a), mildly azotemic cats (b) and moderately azotemic cats 




Figure 4.2 Serum gastrin levels are significantly elevated in severely azotemic 
CKD cats. Cats with severe azotemia had significantly higher serum gastrin 
concentrations when compared to non-azotemic controls (a) when analyzed with 





Inter-observer variation in histologic scoring was compared between pathologists, yielding an 
average kappa coefficient of 0.84 (range 0.78-0.91) for all gastric and renal histologic categories. 
Of the 37 CKD cats and 12 controls, three sections from each anatomic location (cardia, fundus, 
body, antrum, and pylorus) were evaluated with the exception of two CKD cats; only one section 
from the body was available for evaluation in these cases. Bilateral kidneys were available for 
evaluation on all study cats with the exception of one CKD cat that only had the right kidney 
available for histologic evaluation. 
Gastric lesion scores in CKD and control cats are summarized in Table 4.3. No gross or 
histologic evidence of gastric mucosal ulcerations, hemorrhage, or edema were observed in 
either CKD or control gastric tissues. No histologic evidence of amyloid deposition, edema, or 
vascular fibrinoid change was observed in CKD or control gastric tissues. Gastric fibrosis 
occurred more frequently in CKD cats when compared to controls using a Mann Whitney test 
(p=0.005). When all groups were compared using a one-way ANOVA, there was a statistically 
significant difference in the degree of fibrosis in severely azotemic CKD cats when compared to 
the non-azotemic control group (p<0.05, Figure 4.3). Fibrosis was absent in the stomachs of 
control cats while some degree of fibrosis occurred in 16/37 (43%) of CKD cats (Figure 4.4). 
Fibrosis was typically superficial, with variable expansion of the lamina propria, and minimal 
nesting of pit and glandular cells in severe cases. Three of nine mildly azotemic cats had a mild 
increase in superficial proprial fibrous connective tissue (Figure 4.4.2). A single mildly azotemic 
cat had moderate thickening of proprial fibrous connective tissue with separation of superficial 
glands (Figure 4.4.3). Two moderately azotemic CKD cats and 8 severely azotemic cats had mild 
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gastric fibrosis. One severely azotemic cat had moderate lamina proprial fibrous thickening and 














Figure 4.3 Gastric glandular atrophy and fibrosis occurred more frequently in CKD cats. 
Fibrosis scores in severely azotemic CKD cats were significantly increased when compared 
to the non-azotemic controls (a) using a one way ANOVA with Bonferroni’s post hoc 






aFibrosis scores and bmineralization scores  for severely azotemic group statistically greater 
than control group (p<0.05) 
cMineralization scores for severely azotemic group statistically greater than mildly azotemic 
group (p<0.05) 
d,eNo statistical difference between any group 
 
 
Table 4.3 Summary of gastric lesions in control and CKD cats. 
Controls Mild Moderate Severe
Stomach Lesions (<1.6 mg.dL) (1.6-2.8 mg/dL) (2.9-5.0 mg/dL) (>5.0 mg/dL)
Amyloid 0 0 0 0
Edema 0 0 0 0
Fibrosisa
0 12 5 7 9
1 0 3 2 8
2 0 1 0 1
3 0 0 0 1
Average score 0 0.56 0.22 0.68
Mineralizationb,c
0 12 9 5 9
1 0 0 0 1
2 0 0 2 3
3 0 0 2 6
Average score 0 0 1.11 1.32
Vascular Fibrinoid 
change 0 0 0 0
Superifical mucosal 
inflammationd
0 4 0 1 3
1 6 7 7 12
2 2 2 1 4
3 0 0 0 0
Average score 0.83 1.22 1 1.05
Mucosal 
erosion/ulceration 0 0 0 0
















Figure 4.4 Representative examples of degrees of gastric fibrosis (1-4) and mineralization (5-8) 
detected in cats with chronic kidney disease (CKD) compared to non-azotemic controls. (1) Control cat 
stomach, body. Glands are tightly packed with minimal lamina proprial connective tissue.  Masson’s 
trichrome. (2) Cat with CKD, body. Mild expansion of fovalae by lamima proprial fibrous connective 
tissue. Masson’s trichrome. (3) Cat with CKD, body. Moderate expansion of fovalea and gastric glands 
by lamina proprial connective tissue. Masson’s trichrome. (4) Cat with CKD, body. Marked separation 
and individualization of gastric glands by fibrous connective tissue. Masson’s trichrome.  (5) Control 
cat stomach, body. Absence of mineral within the mucosa. Von Kossa. (6) Cat with CKD, body. Mild, 
patchy mineralization. Von Kossa. (7) Cat with CKD, body. Moderate, multifocal to coalescing 
mineralization. Von Kossa. (8) Cat with CKD, body. Severe, diffuse, serpentine pattern of 
mineralization in the apical ½ to 1/3 of the mucosa. Von Kossa 
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Gastric mineralization was more likely to occur in cats with CKD than non-azotemic cats 
(p=0.0214) when compared using a Mann Whitney test. When all groups were compared using a 
one-way ANOVA, gastric mineralization scores were significantly greater in cats with severe 
azotemia compared to non-azotemic and mildly azotemic cats (p<0.05, Figure 4.5). A total of 14 
CKD cats (38%), all from the moderate and severe azotemia groups had gastric mineral of 



















Figure 4.5 Gastric mineralization was present in moderately and severely azotemic CKD 
cats. Gastric mineralization scores were significantly greater in cats with severe azotemia 
when compared to non-azotemic and mildly azotemic cats using a one way ANOVA with 




Within the gastric mucosa of 3 cats karyorrhectic debris was strictly associated with the 
presence of proprial mineral. Mineral was not found in sections of stomach from non-azotemic 
control or mildly azotemic CKD cats. Moderately azotemic cats had multifocal to coalescing 
(n=2) and diffuse (n=2) gastric mineral. Mineralization was evident in 10/19 cats (52%) of cats 
in the severe azotemia group. A single severely azotemic cat had mild, scattered gastric mucosal 
mineral. Diffuse, marked mucosal mineralization that formed a serpentine band across the 
mucosa was prominent in 6 cats with severe azotemia. The remaining 3 had multifocal to 
coalescing patches of mucosal mineral. In addition, 3 cats with gastric mineralization (moderate 
azotemia: 1 cat; severe azotemia: 2 cats) also had mineralization of gastric arteries and arterioles. 
One of these cats had vascular mineralization that was so severe that the tunica media and tunica 
intima of coronary arteries and the aorta were affected.  
There was no statistically significant difference in inflammation scores between any 
groups. Lymphocytic aggregates forming nodules deep within the mucosal lamina propria with 
variable expansion were present in 21/37 (57%) CKD cats and 8/12 (67%) control cats. Follicles 
were not factored into presence or severity of inflammation in either group. Six control cats had 
mild inflammation and 2 had moderate inflammation, which was nearly exclusively lymphocytic 
in character. A single control cat had intraepithelial globular leukocytes present superficially. 
Severe inflammation was not detected in any control or CKD cat. Seven mildly azotemic cats 
had mild superficial inflammation which involved no more than 1/3 of the section. Two 
additional cats with mild azotemia had moderate inflammation involving 30-60% of the section. 
Leukocytic infiltrates primarily were mononuclear (lymphocytes with few plasma cells) while 5 
cats had intraepithelial globular leukocytes that ranged from 0-6 per high-power field. The 
majority (7/9) of moderately azotemic cats had mild inflammation with only a single cat (1/9) 
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with moderate inflammation. Mononuclear inflammatory cells (predominantly lymphocytes with 
occasional macrophages and/or plasma cells) frequently aggregated around mineral when present 
in the moderately azotemic group of cats. Mild inflammation also predominated in cats with 
severe azotemia (12/19). An additional 4 cats with severe azotemia had moderate inflammation. 
Within the group of severely azotemic cats, infiltrates in addition to lymphocytes included 
frequent neutrophils and occasional eosinophils. In a single cat with severe azotemia, eosinophils 
were aggregated around mineral.  
Renal lesions in the CKD group were consistent with those previously reported including 
interstitial fibrosis, interstitial nephritis, and tubular atrophy and glomerulosclerosis.17 Frequency 
and severity of renal fibrosis in study cats are summarized in Table 4.4. The fibrosis score in 
CKD kidneys was significantly greater than that in controls (p<0.001) when compared using a 
Mann Whitney test. When groups were compared using a one-way ANOVA, renal fibrosis 
scores were significantly higher in all CKD groups in comparison to controls (p<0.05). Renal 









In this study CKD cats were more likely to have gastric mineralization, fibrosis, elevated CPP 
and increased serum gastrin levels than non-azotemic controls. Mineralization was only observed 
in cats with moderate and severe azotemia, and CPP increased significantly with degree of 
azotemia. Lesions in CKD cats were restricted to mucosal mineralization and fibrosis, while 
classic uremic gastropathy lesions such as gastric ulceration, amyloid deposition, edema, 
vascular fibrinoid change and hemorrhage were not observed in the cats examined. These 
findings are unique because no studies have previously reported the prospective and systematic 
evaluation of uremia-induced gastric lesions in cat with CKD. These findings also have 
important clinical implications as they suggest that gastrointestinal signs seen in CKD cats may 
be more likely to be the result of uremic toxins and centrally acting emetogens as opposed to 
pathology within the stomach.  
Gastric mineralization was a common finding in cats with CKD in this study, as also 
reported in canines.8 Thirty-eight per cent of stomachs evaluated from cats with CKD contained 
mineral within the mucosal lamina propria. Only cats with moderate and severe azotemia had 
mineralization, suggesting that worsening azotemia and associated derangements in calcium and 
phosphorus concentrations put the cats at risk for soft-tissue mineralization, specifically in the 
stomach. In this study, CPPs tended to be higher in those cats with gastric mineral (114.6) 
compared to those without mineralization (82.58), which approached statistical significance. In 
general, animals with a CPP exceeding 60-70 are at risk for soft tissue mineralization, although 
increased concentrations likely need to be present for weeks to months.18 Development of gastric 
mineralization may vary depending on individual patient factors or variation in the timeframe of 
elevated plasma mineral concentrations (i.e. months versus days). The administration of 
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phosphate binders did not appear to affect the presence of gastric mineralization; however it is 
difficult to assess the efficacy of phosphate binder therapy from this study as duration of 
hyperphosphatemia, duration of therapy and individual trends in calcium and phosphorus during 
the course of treatment are not known for these patients. In addition relatively small numbers of 
cats were receiving phosphate-binder therapy (7/18 severely azotemic cats), which is consistent 
with a recent survey of medication practices in CKD cats in which 78.3% of cats with CKD were 
not receiving phosphate binders.19 The extent to which gastric mineralization contributes to 
clinical signs of uremia is unclear and additional studies are needed to fully elucidate the 
pathophysiology of gastric mineralization in cats with CKD. 
Fibrosis in the superficial mucosa of the gastric body was a common lesion in cats with 
CKD. Evaluation of fibrosis and atrophy was restricted to the body due to variability in glandular 
density and lamina propria connective tissue in other gastric regions.20 Typically, atrophic 
gastritis is the result of chronic inflammation leading to loss of gastric glands and replacement by 
fibrosis; however significant amounts of inflammation were not seen in CKD cats in this 
study.21-23 Disorders leading to atrophic gastritis in humans are predominantly Helicobacter 
pylori infections or autoimmune gastritis.21 Conversely, atrophic gastritis in dogs and cats is not 
frequently reported and a causative relationship between Helicobacter spp. infection and disease 
is equivocal.20 In a single study investigating non-inflammatory atrophy and/or fibrosis, 27% of 
vomiting dogs and 26% of clinically asymptomatic dogs had similar lesions.23 Despite the 
statistically significant difference between controls and CKD cats, the role of azotemia and 
uremia in the pathogenesis of gastric fibrosis is unclear. A limitation of this study was that 
control cats were not aged matched; thus age variation between the two groups is one possible 
explanation for this difference. The amount of fibrous connective tissue normally found in 
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different locations of the cat stomach at different ages has not been established. Additionally, 
without corroborative pathologic evidence of edema, or other evidence of mucosal injury 
preceding the glandular loss and fibrosis, the interpretation that uremia leads to gastric fibrosis 
should be made with caution. Future studies evaluating cross sectional connective tissue density 
amongst similarly aged animals is necessary in order to draw further conclusions. 
Median serum circulating gastrin concentrations were nearly three times greater in 
azotemic cats than non-azotemic cats. Hypergastrinemia in CKD cats reported here is similar to 
findings in previously published reports.5 Gastrin signals the release of hydrochloric acid from 
parietal cells. Hypergastrinemia may lead to hyperacidity and potential chemical damage to the 
gastric mucosa. Despite this reasonable theory for the pathogenesis of uremic gastropathy, 
gastric ulceration was not found in CKD cats in this study, even when serum gastrin 
concentrations were markedly elevated. Hypergastrinemia may strictly be a consequence of renal 
disease. More than one third of plasma gastrin is extracted from circulation in a single pass 
through the kidney by renal cortical inactivation.24 In one study in humans, hypergastrinemia 
correlated with loss of functional renal mass, but not the degree of uremia.24 Gastrin 
concentrations did not necessarily correlate with severity of azotemia in the CKD cats in this 
study, although this has been documented in a previous study.5 Alternatively, in concordance 
with the fibrotic changes found in this study, increased concentrations of gastrin may be the 
result of atrophic gastritis, with reduced gastric acid secretion failing to give appropriate negative 
feedback. The data presented here showed a significant difference in the presence and severity of 
fibrosis in cats with CKD in comparison to controls. However, it is difficult to determine the role 
of renal disease in development of gastric fibrosis based on this information. Appropriate 
morphometric density studies of parietal cells within the gastric mucosa and measurement of 
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gastric acid pH are needed to determine the exact role of hypergastrinemia in gastric pathology 
in cats with CKD.   
Inflammation and lymphoid hyperplasia were similar in the stomachs of CKD and control 
cats. Therefore, their presence was likely unrelated to renal disease, or perhaps within normal 
limits of leukocyte constituents of the feline gastric mucosa. Studies characterizing leukocyte 
subpopulations within the superficial gastric mucosa have been performed in dogs, and standards 
for infiltrates within a defined unit have been described.14,15 Similar studies have not been 
reported in cats. 
In conclusion, cats with CKD appear more likely to have gastric fibrosis and 
mineralization, rather than uremic gastropathy lesions previously described in dogs and humans. 
Therefore, the administration of gastric protectants such as sucralfate may not be justified, unless 
obvious clinical evidence of gastrointestinal hemorrhage such as melena or hematemesis is 
appreciated. The notable frequency of gastric mineralization, presumably as a consequence of 
metastatic mineralization, may highlight the need for more aggressive control of 
hyperphosphatemia and renal secondary hyperparathyroidism in cats with CKD. Gastrointestinal 
symptoms in these animals may not necessarily be the result of gastric lesions, but perhaps the 
consequence of circulating uremic toxins interacting with the chemoreceptor trigger zone in the 
brain. Medical management of gastrointestinal symptoms with anti-emetic and anti-nausea drugs 
may therefore be more appropriate. Lastly, the exact role of hypergastrinemia in contributing to 
gastric hyperacidity and/or gastric lesions in cats with CKD is still unclear. Further studies to 
determine gastric acidity and parietal cell density in cats are needed in order to close this gap in 
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CHAPTER 5: IDENTIFICATION AND QUANTIFICATION OF ANTI-α-ENOLASE 
ANTIBODIES IN SERA OF CATS WITH CHRONIC KIDNEY DISEASE AND 
IMMUNOPRECIPITATION OF ENDOGENOUS RENAL PROTEINS 
5.1 Chapter Summary 
Feline chronic kidney disease (CKD) is a leading cause of morbidity and mortality in aged cats.  
While progress has been made to better characterize and stage feline CKD little is known in 
regards to why CKD is so prevalent in this species or the underlying etiology.  It has been shown 
that parenteral administration of vaccines against feline viral rhinotracheitis (feline herpesvirus 
1), calicivirus, and panleukopenia (FVRCP) or cell lysates (CRFK) used to grow the viruses or 
CRFK lysates alone can induce autoantibodies that bind α-enolase protein.  In addition, a subset 
of these cats with antibodies against CRFK lysates developed interstitial nephritis.  The focus of 
this study was to determine if cats with CKD have anti-α-enolase antibodies by western blot 
immunoassay and if antibody levels are associated with stage of disease or recent vaccination. 
Additionally, to determine if circulating antibodies target endogenous renal α-enolase.  Alpha-
enolase antibodies were quantitated in cats with naturally-occurring CKD (n=29) and healthy, 
unvaccinated controls (n=8) by indirect enzyme-linked immunosorbent assay (ELISA).  Cats 
with CKD had significantly greater levels of α-enolase antibodies than controls (p<0.0001).  
Levels of α-enolase antibodies between IRIS stages were not significantly different (p>0.05).  A 
relationship between levels of antibodies and vaccination status could not be determined due to 
incomplete vaccine histories in a majority of study cats.   Immunoglobulin present within the 





Chronic kidney disease (CKD) is a significant healthy concern in geriatric cats affecting 
anywhere from 28-50% of felines.1, 2  Feline CKD is characterized clinicopathologically by 
increased concentrations of serum creatinine and blood urea nitrogen, decreased urinary 
concentrating ability with variable electrolyte and acid-base derangements.2, 3  Histologically, 
tubulointerstitial lesions predominate.3, 4  Tubulointerstitial lesions consist of interstitial fibrosis, 
inflammation, with tubular degeneration and atrophy.4, 5 Multifactorial etiologies are often cited 
in the genesis of CKD in cats, although little headway has been made in definitively defining the 
etiopathogenesis in this species. 
Vaccines and the cell lines used in the production of viral vaccines have been associated 
with development of interstitial nephritis in cats.6  Feline viral rhinotracheitis, calicivirus, and 
panleukopenia (FVRCP) vaccine is a core vaccine recommended by the American Feline 
Practitioners to be given every 3-4 weeks starting as early as 5 weeks until 16 weeks of age 
followed by every 1-3 years depending on risk.7   Viruses included in some FVRCP vaccines are 
grown on cell cultures derived from feline renal tissues (Crandell Rees feline kidney, CRFK) that 
have been described as “epithelial-like”.8  While the manufacturer’s attempt to exclude all cell 
lines during vaccine production some contamination is likely.  Parenteral administration of 
FVRCP vaccines and CRFK lysates has been shown to induce an antibody response to CRFK 
and renal cell lysates.  In a subset of cats that were hyperinoculated with CRFK lysate, interstitial 
nephritis was evident.6, 9  The majority of cats had significant amounts of vaccine induced 
antibodies that targeted α-enolase.10  It has yet to be determined what the effect of vaccinations 
over the course of a lifetime has on feline autoantibody levels or renal health.  
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Alpha-enolase autoantibodies have been implicated in a variety of autoimmune diseases 
with associated nephritis such as systemic lupus erythematosus (SLE), mixed cryoglobulinemia, 
rheumatoid arthritis, and Sjogren’s syndrome.11-13  Patients with SLE which go on to develop 
lupus nephritis had significant elevations in α-enolase antibodies in serum that were associated 
with proteinuria and increased serum creatinine concentrations.14  Alpha-enolase, a ubiquitous 
glycolytic enzyme, has been identified as a podocyte antigen which is the target for serum 
autoantibodies in lupus nephritis patients.14  Alpha-enolase in the glomeruli of lupus nephritis 
patients is overexpressed when compared to patients without nephritis, however, the cause for up 
regulation is unclear.12  A relationship between naturally occurring CKD in cats and the presence 
of renal specific autoantibodies has not been explored and is the aim of the current study.   
5.3 Methods and Materials 
5.3.1  Samples 
Cats with CKD presenting to Colorado State University Diagnostic Medical Center for necropsy 
from 2012 to 2014 that had an available serum sample were used for this study.  Residual serum 
remaining from routine ante mortem biochemistry were collected and stored at -20oC until assays 
could be batched.  Serum from 8 young (≤1.5 years), laboratory reared, non-azotemic cats 
without previous history of vaccination or renal disease were included as controls.  Parenteral 
FVRCP vaccination histories were collected from medical records for CKD cats when available. 
5.3.2 Clinicopathologic Data 
Using the IRIS staging scheme for CKD, study cats were assigned into a stage between II and IV 
based on elevated serum creatinine concentration, a urine specific gravity <1.035, and clinical 
history consistent with CKD.15  Cats with a normal serum creatinine concentration (<1.6 mg/dl), 
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which include IRIS Stage I, were not included.  Stages II, III, and IV were defined by serum 
creatinine concentrations measuring 1.6-2.8 mg/dl, 2.9-5.0 mg/dl and >5.0 mg/dl, respectively. 
Non-azotemic control cats had no clinical evidence or history of renal disease, USG >1.035, and 
serum creatinine concentration ≤ 1.6 mg/dl. 
5.3.3 Western blot Immunoassay 
Optimized gel electrophoresis and western blot immunoassays were run similar to that 
previously described.10  Alpha-enolase antigen was prepared as follows: 3 ug ENO1 recombinant 
protein (Abnova, Taiwan Corp) was mixed with lithium dodecyl sodium (LDS) sample buffer, 
reducing agent, denatured and loaded on a precast 10% Bis-Tris mini gel along with a molecular 
weight standard (Thermo Scientific).  Gels were electrophoresed in 3-(N-Morpholino)-
propanesulfonic acid running buffer at 200V for 50 minutes.  Proteins were then transferred to a 
polyvinylidene difluorure (PVDF) membrane in transfer buffer with 20% methanol in a XCell II 
Blot Module (NuPage, Intitrogen, Carlsbad) at 25V for 90 minutes.  Membranes were dried at 
room temperature and stored at -20oC.   
When all samples had been collected membranes were thawed, moistened with methanol, 
rinsed in distilled water, and blocked with 1xNEH at room temperature with gentle rocking for 1 
hour.  Samples were loaded into Miniblotter 28 (Immunogenics) at an optimized dilution of 1:20 
in TNTP-10% milk at room temperature with gentle rocking for 2 hours.  Membranes were 
rinsed with PBS-Tween 80 for 5 minutes for a total of three washes then incubated with 
peroxidase labeled goat anti-cat IgG (γ) secondary antibody (Kirkegaard and Perry Laboratories, 
Gaithersburg, MD) in a 1:25 dilution in TNTP-10% milk for 1 hour at room temperature with 
gentle rocking.  Membranes were rinsed three times for 5 minutes in PBS-Tween 80.  Protein 
bands were visualized by colorimetric horseradish peroxidase (HRP) detection with 3, 3'-
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diaminobenzidine in 10% hydrogen peroxide buffer and analyzed by Quantity One (Bio-Rad) 
software. 
5.3.4 Enzyme-linked immunosorbent assay (ELISA) 
Optimized α-enolase enzyme-linked immunosorbent assay (ELISA) was run on samples as 
previously described.10  Briefly, each well of a 96-well plate (Immulon II, ThermoScientific, 
Waltham, MA) were incubated with 10 ng of recombinant α-enolase in 100 microliters of 0.06 M 
carbonate buffer (pH 9.6) overnight at 4oC.  Wells were washed with 0.05% Tween 20-PBS 
(PBS-TW) 3 times.  Previously determined positive and negative controls and test samples were 
diluted 1:40 in PBS-TW at 400 microliters per well, loaded in triplicates, and incubated at 37oC 
for 30 minutes.  Wells were washed 3 times in PBS-TW.  Peroxidase labeled goat anti-cat IgG 
(γ) secondary antibody (Kirkegaard and Perry Laboratories, Gaithersburg, MD) was diluted 
1:100 in PBS-TW at 100 microliters per well, and incubated at 37oC for 30 minutes.  Wells were 
washed with PBS-TW as previously described and 100 microliters per well of TMB (Kirkegaard 
and Perry Laboratories, Gaithersburg, MD) was incubated at room temperature (20oC) for 10 
minutes.  Color reaction was stopped with 100 microliters of 0.18M H2SO4 per well.  Optical 
density was read by an automatic plate reader at 450nm and results were reported as the mean 
absorbance of triplicates (Ascent Multiskan, ThermoScientific, Waltham, MA).  The mean 
absorbance was converted to %ELISA by dividing the difference between the test sample mean 
absorbance and negative control mean absorbance by the difference between the positive and 
negative control mean absorbance and multiplying by 100. 
5.3.5 Immunoprecipitation (IP) 
Renal cortex from a non-azotemic, healthy cat was homogenized and desalted by acetone 
precipitation.  Protein was quantified by BCA protein assay (ThermoScientific).  A commercially 
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available classic immunopreciptiation kit (ThermoScientific) was used to complex purified 
immunoglobulin G from pooled α-enolase positive serum of CKD cats and monoclonal mouse 
alpha-enolase antibody with feline renal tissue homogenate.  Immunoglobulin from CKD cats 
was titrated at 2, 5, and 10 ug with 500 ug of renal protein.  Alpha-enolase mouse monoclonal 
antibody was titrated at 1, 2, and 5 ug and complexed with a total of 250ug of protein for each 
dilution.  Homogenized renal tissue was pre-cleared according to the manufacturer’s protocol 
and immune complexes were prepared by incubating at 4oC overnight.  Immune complexes were 
captured on a Protein A/G agarose resin column and eluted off with sample elution buffer and 
heating.  Immune complexes were run on a 10% B is-Tris gel in LDS buffer for 50 minutes at 
200V.  Protein bands were visualized with SimpleBlue stain (Life Technologies), rinsed in dH2O 
and then 20% ethanol.  Bands were excised, subject to trypsin digestion, and mass spectrometry 
at the Colorado State University Proteomics and Metabolomics Facility. 
5.3.6 Mass Spectrometrry 
Sample peptides were purified and concentrated utilizing an on-line enrichment column prior to 
chromatographic separation on a reverse phase nanospray column (Thermo Scientific).  Spectra 
of eluted peptides were collected from a mass spectrometer (Thermo Scientific Orbitrap Velos) 
over a m/z range of 400-2000 Da with a dynamic exclusion limit of 2 MS/MS spectra of a 
peptide mass for 30 seconds (exclusion duration of 90 seconds).  Resulting spectra was generated 
using Xcalibur 2.2 software (Thermo Scientific) with a signal-to-noise ratio threshold of 1.5 and 
1 scan/group. 
Tandem mass spectra were extracted, charge state was deconvoluted and deisotoped by 
ProteoWizard (MSConvert) version 3.0.   MS/MS samples were analyzed by Mascot (Matrix 
Science, London, UK; version 2.3.02) set up to search the uniprot_feline_rev_100214 database 
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(unknown version, 42512 entries).  Searches were performed assuming trypsin digestion, with a 
fragment ion mass tolerance of 0.80 Da, and a parent ion tolerance of 20 PPM. Oxidation of 
methionine and carbamidomethyl of cysteine were specified in Mascot as variable modifications. 
Scaffold (version Scaffold_4.4.1.1, Proteome Software Inc., Portland, OR) was used to validate 
MS/MS based peptide and protein identifications. Peptide identifications were accepted if they 
could be established at greater than 95.0% probability by the Scaffold Local FDR algorithm. 
Protein identifications were accepted if they could be established at greater than 99.9% 
probability and contained at least 2 identified peptides. Protein probabilities were assigned by the 
Protein Prophet algorithm.16  Proteins that contained similar peptides and could not be 
differentiated based on MS/MS analysis alone were grouped to satisfy the principles of 
parsimony. 
5.3.7 Statistics 
To investigate an association between the presence of anti-α-enolase antibodies in the serum of 
cats with or without CKD and between CKD groups (i.e. vaccine status and IRIS stage) was 
determined by Fisher’s exact test and chi-square analysis, respectively.  A non-parametric t test 
(Mann Whitney) was used to compare mean absorbance and %ELISA results between controls 
and CKD cats while a non-parametric one-way analysis of variance (Kruskal Wallis) was used to 
compare mean absorbance and  %ELISA results between CKD groups (i.e. vaccine status and 
IRIS stage) with a post hoc Dunn’s multiple comparison.  Correlation analysis of ELISA assays 
and serum creatinine concentrations were achieved by a non-parametric Spearman rank 
correlation.  All statistical analyses were performed on GraphPad Prism version 5.00 for 
Windows (GraphPad Software, San Diego California USA, www.graphpad.com).  Statistical 





A total of 29 CKD cats classified into Stages II-IV as well as 8 healthy, non-azotemic control 
cats were included in this study.  Control cats were ≤1 ½ years old, domestic shorthair, and 
consisted of 2 males and 6 females.  Mean serum creatinine concentration for control cats was 
1.1 md/dl (range 0.9-1.6 md/dl). A total of 9 Stage II cats, 8 Stage III and 12 Stage IV CKD cats 
were included in this study.  The mean age of cats with CKD was 14.7 years (range 8-20 ½ 
years) and included 14 castrated male and 15 spayed female cats.  Domestic shorthair cats were 
most prevalent (n=17) with lesser domestic longhair (n=6), 3 Siamese, 1 Tonkinese, and 1 
Ragdoll breeds. The mean serum creatinine concentration for Stage II cats was 2.3 mg/dl (range 
1.8-2.7 mg/dl), Stage III 3.5 mg/dl (2.9-4 mg/dl), and Stage IV 8.2 mg/dl (4.2-12.6 mg/dl).  
Vaccine histories were collected from medical records and primary veterinarians were contacted 
to confirm dates, routes of administration, and type of FVRCP vaccine given.  This information 
was only available for 9/29 CKD cats.  Because of the limited number of cats with available 
vaccine histories statistical comparisons of antibody levels were not analyzed. 
5.4.2 Western Blot Immunoassay 
Of the 29 CKD cats, 19 were positive for α-enolase antibodies while 10 were negative by 
Western blot (Figure 5.1).  The mean molecular weight (MW) of CKD bands was 72.7 kDa. Five 
Stage II cats, 6 Stage III, and 8 Stage IV cats had anti-α-enolase antibodies in serum by western 
blot. All eight control cats were positive for anti-α-enolase antibodies with a mean band MW of 
71.8 kDa.  The theoretical molecular weight for recombinant α-enolase protein was 73.5 kDa.  
No association was found between the presence of anti-α-enolase antibodies in serum and cats 
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with or without CKD by western blot (p=0.08).  A majority of CKD cats in each stage had α-
enolase antibodies in serum albeit a statistically significant association was not found (p=0.70).   
  
 
       1             2       3      4       5      6      7       8      9     10     11    12    13    14     15    16    17     18 
Figure 5.1 Alpha-enolase western blot with cat serum.  Lane 1 is the molecular weight standard 
at 64 kDa.  Mean band molecular weight is approximately 72kDa. (Lane 2 and 3) control cats, 





Results from α-enolase ELISAs are summarized in Table 5.1.  The mean absorbance for α-
enolase ELISAs in healthy, non-azotemic control cats was 0.44 (standard error of the mean 0.06) 
which was significantly less than CKD cats (1.21±0.10, p<0.0001; Figure 5.2). The median 
%ELISA for α-enolase antibodies in 8 control cats was 0 (range 0-23.6) while CKD cats were 
significantly greater at 77.47 (range 0-371.9; p<0.0001; Figure 5.3).   
 
 
Mean absorbance values for α-enolase in non-azotemic, healthy control cats were 
significantly less than CKD cats at all IRIS stages (p<0.05, Figure 5.4).  Median α-enolase 
%ELISA measurements for control cats were less than all CKD stages, however, statistical 
significant difference was only found between controls and CKD Stages III and IV (p<0.05, 
Figure 5.5).   
  
 
Table 5.1 Mean absorbance and calculated %ELISA results of α-enolase ELISA.  
%ELISA measurements were determined by the following equation: (mean absorbance 
test sample-mean absorbance of negative control) / (mean absorbance of the positive 





















Figure 5.2 Mean absorbance for α-enolase 
ELISA. CKD cats had significantly higher α-




Figure 5.3 %ELISA for the α-enolase ELISA. 
CKD cats had significantly higher α-enolase 
antibodies than healthy controls, p<0.001. 
  
Figure 5.5 %ELISA for α-enolase ELISA by 
IRIS stage. Healthy controls had significantly 
less α-enolase antibodies than CKD cats at 
Stages III and IV, p<0.05. 
Figure 5.4 Mean absorbance for α-enolase 
ELISA by IRIS stage. Healthy controls 
had significantly less α-enolase antibodies 
than CKD cats at Stages II-IV, p<0.05. 
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The mean absorbance of α-enolase by ELISA increased with increasing IRIS stage; 
however, the results were not statistically significant (Figure 5.4).  Stage II cats had a mean 
absorbance of 1.05 (± 0.15) and a median %ELISA value of 69.67 (range 0-158.8).  Stage III 
cats had a mean absorbance of 1.17 (±0.09) and median %ELISA of 80.13 (range 20.8-122.4); 
while Stage IV cats had a mean absorbance of 1.35 (±0.20) and median %ELISA value of 83.47 
(range 42.6-371.9).  No difference in %ELISA measurements was found among IRIS stages 
(Figure 5.5).   
No significant correlation between either mean absorbance (r=0.20, p=0.29) or %ELISA 
(r=0.21, p=0.28) and serum creatinine concentration of CKD cats was found (Figures 5.6 and 
5.7).  Removal of single outliner did not make data statistically significant.  Additionally, the 
mean absorbance and %ELISA from CKD cats that were negative by α-enolase western blot and 
those that were positive were not statistically different (p=0.19; Figures 5.8 and 5.9 ).  If western 
blot negative cats were removed from the analysis, detectable α-enolase antibody by ELISA 
remained significantly greater than controls (mean absorbance, p=0.0002; %ELISA, p=0.0003; 







Figure 5.7 Spearman correlation of 
%ELISA and serum creatinine for CKD 
cats.  No significant correlation was 
found (r=0.21, p=0.28) 
Figure 5.6 Spearman correlation of Mean 
absorbance and serum creatinine for CKD 
cats.  No significant correlation was found 
(r=0.20, p=0.29). 
 
Figure 5.8 Mean absorbance for α-enolase 
ELISA.  CKD cats that were negative by 
western blot immunoassay did not have 
significantly different levels of α-enolase 
antibodies by ELISA, p=0.19. 
 
Figure 5.9 %ELISA for α-enolase ELISA.  
CKD cats that were negative by western 
blot immunoassay did not have 
significantly different levels of α-enolase 













5.4.4 Immunoprecipitation (IP) and Mass Spectrometry 
Immunoglobulin G eluted from serum by affinity chromatography was incubated with feline 
renal cortical homogenate.  Elutes were run on PAGE and bands excised for mass spectrometry.  
Protein bands were present in all immunoglobulin dilutions.  Eluted heavy chain 
immunoglobulin protein bands (50 kDa) were not distinct from eluted antigen in the CKD 
samples and the entire band was submitted for proteomics.  A total of 30 proteins with 100% 
protein identification probability were found in the protein band excised from CKD 
immunoprecipitation (IP) gel.  Nineteen proteins with 100% protein identification probability 
were identified from monoclonal α-enolase antibody IP gel.  Enolase was identified in the feline 
renal homogenate precipitated with recombinant α-enolase antibody along with numerous keratin 
contaminates.  Enolase was not found from excised gel bands in the CKD sample.  A majority of 
proteins identified were keratin contaminates.  However, when elutes were analyzed by mass 
 
Figure 5.10 Mean absorbance for α-
enolase by ELISA.  Control cats had 
significantly less α-enolase antibodies than 
western blot positive CKD cats, p=0.0002. 
Figure 5.11  %ELISA for α-enolase by 
ELISA.  Control cats had significantly less 
α-enolase antibodies than western blot 




spectrometry prior to gel electrophoresis α-enolase was identified from feline renal homogenate 
precipitated with CKD immunoglobulin at 2 and 5 ug titrations. 
5.5 Discussion 
Spontaneous development of anti-α-enolase antibodies in serum have been shown to be 
associated with nephritis in humans with autoimmune diseases.12, 17  In cats, autoantibodies to α-
enolase can be induced with parenteral administration of FVRCP vaccine.9, 10  Additionally, 
inoculation with the vaccine contaminate, CRFK lysates, has been linked to the development of 
interstitial nephritis in hyperinoculated cats--a common lesion seen in cats with naturally 
occurring kidney disease.6  Our findings show that cats with CKD do develop significant levels 
of anti-α-enolase antibodies detectable by serum ELISA when compared to healthy, non-
azotemic controls.  While there was subtle increases in the mean absorbance measurements 
between CKD stages no statistically significant association between serum creatinine 
concentrations or IRIS stage and antibody levels were found.  Due to unavailable vaccine 
histories for all study cats an association between parenteral FVRCP and α-enolase antibodies in 
CKD cat sera could not be determined.  Future directions in determining this relationship would 
include similar assays with sample sets from age-matched cats with and without CKD and 
detailed vaccine histories which would include the route of administration, type of vaccine (e.g. 
modified live), frequency and timeframe of vaccination from sample date. 
Ten CKD cats were negative on western blot immunoassay but had detectable levels of 
α-enolase antibodies by ELISA. Those cats that were negative for α-enolase antibodies by 
western blot did have less mean absorbance and %ELISA measurements compared to CKD 
western blot positive CKD cats; however, this difference was not statistically significant (Figures 
5.8 and 5.9). Alpha-enolase western blot immunoassay could be a less sensitive method of α-
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enolase antibody detection compared to ELISA.  However, all control cats were positive by 
immunoblot but had significantly less antibody by ELISA than immunoblot negative CKD cats 
negative cats (p=0.002). A potential reason for this discrepancy could be from failure of protein 
transfer from the gel to the PVDF membrane in those particular locations, however, negative 
samples were spread out over the membrane and not necessarily concentrated to one location.  
Lastly, α-enolase antibody in sera of cats with CKD could have low affinity binding for 
recombinant α-enolase resulting in reduction in the level of detection by immunoblot.18, 19   
Alpha-enolase was sequenced by mass spectrometry from immunoprecipitated cat sera 
and recombinant, monoclonal antibody with feline kidney homogenate.  The absence of 
identifiable α-enolase by mass spectrometry in gel bands from immunoprecipitated cat sera could 
be the consequence of interference of immunoglobulin heavy chain.14  It is likely that due to 
confluent bands between the location of Ig heavy chain (50 kDa) and the protein of interest (47 
kDa) on the gel that immunoglobulin was included with excision of the sample band.  Exclusion 
of immunoglobulin could be achieved by a different immunoprecipitation technique that 
covalently binds antibody to the IP agarose matrix allowing for elution of only the antigen 
(Thermo Scientific). Despite potential interference of Ig heavy chain whole elution’s of feline 
immunoglobulin and precipitated kidney homogenates yielded identification of α-enolase with 
100% protein identification probability. A potential cause for this discrepancy between the crude 
elution and the gel band could be in the method of band excision.  Perhaps gel bands were 
excised or handled incorrectly yielding mostly keratin contaminants by mass spectrometry.   It is 
our opinion, based on the results of this assay, that immunoglobulin present within CKD cat sera 
binds endogenous renal α-enolase.  
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In conclusion, the findings of this study show that cats with naturally occurring CKD 
have high levels of serum anti-α-enolase antibodies.  While cats with CKD have significantly 
greater amounts of α-enolase autoantibodies when compared to healthy controls, no significant 
difference was found when comparing groups based on severity of disease (i.e. IRIS stage).  
Lastly, immunoglobulin present within the serum of cats with CKD is capable of binding 
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CHAPTER 6: QUANTIFICATION OF RENAL α-ENOLASE IN FELINE CHRONIC KIDNEY 
DISEASE 
6.1 Chapter Summary 
Alpha-enolase, a ubiquitous, glycolytic enzyme known for catalyzing the conversion of 3-
phosphoglycerate to phospheenolpyruvate has been implicated as a self-antigen in various 
autoimmune diseases.  Autoantibodies in serum are capable of eliciting renal injury and 
ultimately can contribute to patient morbidity and mortality.  Furthermore, endogenous renal α-
enolase has been shown to be overexpressed in human patients with systemic lupus nephritis and 
mixed cryoglobulinemia.  Kidney disease is common in companion animals and affects a 
significant proportion of geriatric cats.  Alpha-enolase protein expression in the kidney has not 
determined in healthy or diseased cats.  The purpose of this study was to identify and 
characterize α-enolase expression in feline tissues as well as to compare the pattern of expression 
between healthy kidneys and kidneys from cats with chronic kidney disease (CKD).  A total of 
29 cats with CKD and 8 non-azotemic, healthy controls were evaluated for this study.  An 
immunohistochemistry technique for semi-quantitative measurement of α-enolase protein 
expression in feline tissue was optimized utilizing a commercially available monoclonal α-
enolase antibody.  In healthy kidneys, α-enolase was moderately expressed in tubular epithelium 
but absent in glomeruli.  In contrast, α-enolase expression was significantly decreased in tubules 
that were degenerative or atrophic in kidneys of CKD cats with significantly more expression in 
glomeruli relative to healthy controls.  There was no significant difference in α-enolase 
expression in hepatocytes between groups.  This study shows that renal α-enolase expression is 




Lohman and Mayerhof in 1934 discovered the glycolytic enzyme, enolase, while studying the 
conversion of 3-phosphoglycerate to pyruvate in muscle extracts.1 To date, enolase has been 
described in both prokaryotic and eukaryotic organisms.  The mammalian enolase enzyme 
family consists of 3 isoenzyme subunits: alpha, beta, and gamma; forming homo- or 
heterodimers.2-6    Alpha-enolase isoezyme is ubiquitous, found in a variety of tissues, with the 
highest concentration within the thymus and kidney.4, 7  This isoform predominates during 
morphogenesis which eventually transitions into beta and gamma dimers with development of 
mature skeletal muscle and nervous tissues, respectively.2, 3, 5, 6  Although originally 
characterized as a cytoplasmic, glycolytic enzyme, enolase has been shown to have multiple 
functions as well as variable cellular expression.4, 8-11  Products of eno1 gene can participate in 
transcriptional repression; cellular defense against hypoxia; and function as a plasminogen 
receptor.12-17      
Circulating α-enolase antibodies have been repeatedly detected in serum of patients with 
autoimmune diseases such as but not limited to rheumatoid arthritis, systemic lupus 
erythematosus (SLE), and mixed cryoglobulinemia.7, 18-22  Of particular interest, 70% of SLE 
patients with detectable anti-alpha-enolase antibodies have active nephritis.22, 23 Renal expression 
of α-enolase is primarily within the cytoplasm of healthy renal tubular epithelium but lacking 
within glomeruli.19, 24  In human patients with lupus nephritis, α-enolase is overexpressed in 
tubules and glomeruli in comparison to healthy patients.19  Similar descriptive or quantitative 
studies of enolase expression in healthy or diseased feline kidneys have not been reported.   
The aim of the current study was firstly to utilize immunohistochemistry to determine 
protein expression of alpha-enolase in feline tissues and compare expression in the kidney 
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between healthy control cats and cats with chronic kidney disease (CKD).  In addition, 
immunoreactivity of α-enolase in liver tissues was used in order to determine if systemic α-
enolase protein expression was affected by CKD.   
6.3 Methods and Materials 
6.3.1 Samples 
Cats with CKD presenting to Colorado State University Diagnostic Medical Center for necropsy 
from 2012 to 2014 were used for this study.  Kidney (n=29) and liver tissues (n=5) from cats 
with CKD was sampled at the time of necropsy. Tissues were fixed in 10% neutral buffered 
formalin solution, paraffin embedded and sectioned at 5 microns.  Liver (n=5) and kidney (n=8) 
tissue from non-azotemic, young (≤1.5 years), healthy cats acquired from the humane society or 
laboratory reared were used as controls, respectively.   Acquisition of tissues was approved by 
Colorado State University’s Institutional Animal Care and Use Committee (IACUC).   Liver 
tissue was sampled and scored in order to determine if systemic α-enolase protein expression 
was variable with chronic kidney disease.  Thymic tissue from a young cat that was euthanized 
unrelated to the current study and necropsied for diagnostic purposes was collected and used for 
antibody optimization and assay validation.  Thymic tissue was used for assay validation and 
optimization due to its reported high level of α-enolase protein expression.7 
6.3.2 Clinicopathologic Data 
Using the IRIS staging scheme for CKD, study cats were assigned into a stage between II and IV 
based on elevated serum creatinine concentration, a urine specific gravity <1.035, and clinical 
history consistent with CKD.25  Cats with a normal serum creatinine concentration (<1.6 mg/dl), 
which include IRIS Stage I, were not included.  Stages II, III, and IV were defined by serum 
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creatinine concentrations measuring 1.6-2.8 mg/dl, 2.9-5.0 mg/dl and >5.0 mg/dl, respectively. 
Non-azotemic control cats had no clinical evidence or history of renal disease, USG >1.035, and 
serum creatinine concentration ≤ 1.6 mg/dl.  
6.3.3 Immunohistochemistry 
Tissues were fixed in 10% neutral buffered formalin solution, paraffin embedded and sectioned 
at 5 microns.  Immunohistochemistry (IHC) on all tissues was performed on a Leica Bond-Max 
autostainer (Leica Microsystems) according to established manufacturer’s protocol.  Tissue 
sections were deparaffinized and rehydrated.  Antigen retrieval consisted of heating slides for 20 
minutes with Bond Epitope Retrievel Solution 1 at pH 6 (Leica Microsystems).  Endogenous 
peroxidase activity was blocked with 3% hydrogen peroxide solution.  Slides were incubated 
with mouse monoclonal ENO1 antibody (Abnova Taiwan Corp.) for 15 minutes at room 
temperature.  Primary antibody was replaced with Bond Ready-to-Use Mouse Negative Control 
antibody for negative controls (Leica Microsystems).  Antibody detection was accomplished by 
applying 3,3’-diaminobenzidine chromagen and hematoxylin counterstain. 
Determining optimal antibody concentration for appropriate signal intensity was 
determined by applying serial dilutions of primary antibody (ENO1, Abnova) to thymic tissue.  
The optimal concentration of antibody that provided the highest intensity with the least 
background staining was 1:2000, compared with more concentrated dilutions (1:500 and 
1:1000).  Primary antibody at a concentration of 1:2000 was used in all IHC procedures as 
described above with thymus as a positive control.  Assay validation was achieved by scoring 
thymic tissue at the optimal antibody concentration on 3 separate occasions and scored 
separately.  Interassay variation was determined from the quotient of the standard deviations and 
mean (i.e. coefficient of variation). 
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  Each section of kidney and liver was evaluated for positive immunoreacitvity and 
assigned a score based on signal intensity—immunoreactivity--ranging from 0 to 3.  Scoring was 
defined as follows:   0=no staining, 1=light brown/tan, 2=moderate brown staining, 3=dark 
brown which may obscure the nucleus.  Ten high powered fields (40X) were selected from a 
subgross grid for each section of liver and kidney.  A total of 20 hepatocytes, 2 per single grid 
block were scored.  Similarly renal cortical tubules, either 20 tubules from controls or 10 injured 
and 10 normal tubules from CKD cats, and 20 non-sclerotic glomeruli for each cat were scored.  
Injured tubules were defined as those that were degenerative or atrophic.  Sections from bilateral 
kidneys were evaluated separately and compared to determine if there was variability between 
kidneys in individual CKD (n=5) and control (n=2) cats.  
6.3.4 Statistics 
Immunoreactivity scores for renal cortical tubules and glomeruli from non-azotemic controls and 
CKD cats were compared by non-parametric one-way analysis of variance (Kruskal-Wallis) with 
post-hoc Dunn’s comparison tests.  Additionally, tubules and glomeruli from bilateral kidneys of 
CKD and control cats were compared by non-parametric, paired t test (Wilcoxon signed rank 
test).  Hepatocytes of controls and CKD cats were compared by a non-parametric t test.  
Statistical significance for all analyses were set at p<0.05 and performed in GraphPad Prism 
version 5.00 for Windows (GraphPad Software, San Diego California USA, 




6.4.1 Signalment and Clinicopathologic Data 
A total of 29 cats with CKD and 8 non-azotemic, young, healthy controls were included in this 
study.  Control cats were ≤1 ½ years old, domestic shorthair, and consisted of 2 males and 6 
females.  A total of 9 Stage II cats, 8 Stage III and 12 Stage IV CKD cats were included in this 
study.  The mean age of cats with CKD was 14.7 years (range 8-20 ½ years) and included 14 
castrated male and 15 spayed female cats.  Domestic shorthair cats were most prevalent (n=17) 
with lesser domestic longhair (n=6), 3 Siamese, 1 Tonkinese, and 1 Ragdoll breeds. 
6.4.2 Immunohistochemistry 
6.4.2.1 Thymus 
Immunohistochemistry of feline tissues utilizing a mouse monoclonal α-enolase antibody 
(Abnova, Taiwan) was validated and optimized with thymic tissue from a young cat without 
renal disease.  At the ideal dilution, 1:2000, the coefficient of variation for interassay variation 
was determined to be 8.2%.   Pale to light staining was present in the cytoplasm of most thymic 
epithelial cells with a mean staining intensity of 0.99 on a visual scale of 0-3.  Infrequently, a 
thin rim of moderate cytoplasmic staining could be identified around small lymphocytic nuclei.  
Determining cytoplasmic versus membrane staining was equivocal in lymphocytes.    
Additionally, periparenchymal adipocytes were positive for cytoplasmic enolase.  
6.4.2.2 Liver 
Hepatocellular α-enolase expression was not significantly different between cats with or without 
CKD (p>0.05, Figure 6.1).  The median immunoreactivity score for young control cats and CKD 
was 1 (range 0-2).  No score of 3 was given to any hepatocyte for either group while a majority 
were given a score of 1 (controls 62/100, CKD 73/100).  Remaining cats were given a score of 
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either 2 (controls 20/100, CKD 12/100) or no staining was detected (controls 18/100, CKD 





Figure 6.2  Immunohistochemistry of the liver from a (1) non-azotemic, healthy control 
and (2) chronic kidney disease cat, mouse monoclonal α-enolase antibody, 20X (Inset: 
negative control). 
 
Figure 6.1 Mean immunoreactivity scores for hepatocytes of healthy controls (n=5) and 




6.4.2.3 Kidney  
Alpha-enolase immunoreactivity scores for CKD and control cats are summarized in Figure 6.3 
with descriptive statistics outlined in Table 6.1.  When comparing bilateral kidney scores from 
either CKD (n=5) or control (n=2) cats statistical difference was not found in staining intensities 
of CKD tubules (injured tubules, p=0.57; normal tubules, p=0.11) and glomeruli (CKD, p=0.77; 
controls, p=0.09).  All tubules from bilateral kidneys of control cats were scored a 2 and so 
statistical analysis could not be performed because all values were equal.  Because no difference 
between kidneys within individual cats was found, either those with CKD or healthy controls, a 





Table 6.1 Summary of immunoreactivity scores in non-azotemic, healthy control cats 
(n=8) and chronic kidney disease cats (n=29).  Immunoreactivity scores are given as the 
















A total of 8 young, non-azotemic, healthy cats were used as controls.  Twenty glomeruli 
and 20 tubules were evaluated per cat.  The median glomerular immunoreactivity score for 
control cats was 1 (range 0-2).  The majority of glomeruli (139/160) had either absent staining 
for α-enolase or occasional pale staining of a few epithelial cells (Figure 6.4).  The median 
tubular immunoreactivity score for control cats was 2 (range 2-3).  Nearly all control cats had 
moderate, monochromatic, cytoplasmic staining of tubular epithelial cells (158/160) with only a 




Figure 6.3 Mean immunoreactivity scores for glomeruli and tubules from healthy controls and 
CKD cats.   Normal and injured tubules in CKD cats were scored separately.  Whiskers 
represent the standard error of mean.  Glomerular α-enolase expression was significantly 
greater in CKD cats than controls (p<0.05).  Tubular α-enolase was significantly greater in 




Twenty-nine cats at various stages of CKD were evaluated for this study.  Glomerular 
staining in CKD cats was variable with a median score of 2 (range 0-3).   Immunopositivity for 
α-enolase was variable even within the same kidney of some cats with some glomeruli having 
absent staining while in other regions staining intensity was marked (Figure 6.5).  However, 
moderate staining was most common (243/580) and present within the cytoplasm of glomerular 
epithelial cells (visceral and parietal) and less frequently mesangial cells.  Degenerative and 
atrophic tubules (i.e. injured) were scored separately from tubules that morphologically were 
normal in cats with CKD.  Injured tubules had a median score of 1 (range 0-3) while 
morphologically normal tubules had a median score of 2 (range 1-3).  There was a greater 
variability in staining intensity in injured tubules while a majority of morphologically normal 
tubules had moderate staining (203/290). 
Glomerular α-enolase expression by immunohistochemistry was significantly greater in 
cats with CKD than controls (p<0.05).  Immunoreactivity was not significantly different between 
morphologically normal tubules and control tubules, however, injured tubules from CKD cats 
had significantly less α-enolase staining than both tubules from control cats and morphologically 







Figure 6.4 Immunohistochemistry of the kidney in a healthy control cat, mouse monoclonal 
α-enolase antibody.  Minimal staining in glomeruli with moderate, monochromatic staining 
of tubules, 20X (Inset: negative control). 
 
 
Figure 6.5 Immunohistochemistry of the kidney in a CKD cat, mouse monoclonal α-
enolase antibody.  There is moderate to marked glomerular staining in epithelial and few 




Immunoreactivity of α-enolase was compared between CKD stages.  Results are 
summarized in Figure 6.6 with descriptive statistics outlined in Table 6.2.  Of the 29 CKD cats 
included in this study 9 were in Stage II, 8 Stage III, and 12 were in Stage IV.  The median 
expression of α-enolase in glomeruli was 2 (range 0-3) for all stages with no statistical 
significance found between stages.  Median immunoreactivity for normal tubules was 2 (range 1-
3) for all stages with no significant difference between stages. Injured tubules of cats at any stage 
of CKD had significantly less α-enolase expression when compared to normal tubules at any 
stage (p<0.05).  The median immunoreactivity score for all stages of injured tubules was 1 
(range 0-3).  No statistically significant difference was found between stages when α-enolase 
expression in injured tubules was compared.  Alpha-enolase expression in glomeruli of CKD cats 
was significantly less than normal tubules at all stages (p<0.05).  Injured tubules from all stages 
had significantly less α-enolase expression than glomeruli from Stage IV cats (p<0.05).  
However, expression was similar between injured tubules of Stage II cats and glomeruli of both 



















Figure 6.6 Mean immunoreactivity scores for glomeruli and tubules from healthy controls and 
CKD cats.   Normal and injured tubules in CKD cats were scored separately.  Whiskers 
represent the standard error of mean.  Glomerular α-enolase expression was significantly 
greater in CKD cats than controls (p<0.05).  Tubular α-enolase was significantly greater in 
control tubules and normal CKD tubules when compared to injured CKD tubules (p<0.05). 
 
Table 6.2 Summary of immunoreactivity scores in CKD cats grouped by IRIS. 
Immunoreactivity scores are given as the total number and (percentage) of glomeruli or tubule 





In this study we have described α-enolase protein expression in feline thymic, hepatic, and renal 
tissues.  We demonstrated that there is a difference between renal α-enolase expression in cats 
with CKD compared to healthy controls.  Renal α-enolase is primarily expressed in renal cortical 
tubules in healthy cats with absent to minimal expression in glomeruli.  In contrast, tubular 
expression was decreased in injured tubules while glomerular expression was increased in CKD 
cats compared to healthy controls.  Alpha-enolase expression in the glomeruli of CKD cats was 
present in the cytoplasm of mesangial cells, visceral and parietal epithelium similar to the pattern 
described in patients with SLE nephritis with the exception of crescents in SLE which was not a 
feature found in CKD cats.19   
The mechanism for α-enolase protein overexpression in the kidney has not been 
definitively determined.19  Possible mechanisms include glycolytic and non-glycolytic pathways 
in response to hypoxic conditions and increased anaerobic metabolism.4, 12, 13  In response to 
hypoxic conditions, endothelial cells but not renal tubular epithelial cells were shown to up 
regulate α-enolase.12, 13, 26  Therefore, at least in cases of SLE nephritis with overexpression of α-
enolase in renal tubules another function for the protein other than glycolysis may be the cause 
for increased levels.  Glomerular expression described in this current study is similar to that seen 
in SLE nephritis biopsies.  Therefore, it seems plausible that up regulation of α-enolase in cats 
with CKD has a similar pathogenesis and function, although at present has not been described.  
Similar mechanisms are likely playing a role in increased protein expression in glomeruli and 
normal tubules of cats with CKD.  The decreased protein expression in injured tubules of CKD 
cats could be the result of tubular degeneration and atrophy a common histologic feature of 
feline CKD.27, 28  Another potential cause for decreased protein expression in injured tubules 
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could be the presence of nephritogenic autoantibodies that are bound to tubular α-enolase and 
thus blocking available epitopes for detection by monoclonal antibody in the 
immunohistochemistry assay.  However, this was not a reported interference for protein 
detection in similar assays with known nephrtiogenic autoantibodies in human patients.19 
Alpha-enolase expression in the liver of cats was not affected by CKD.  
Immunoreactivity was mild in both CKD and healthy control groups.  Thymic α-enolase 
immunoreactivity in both CKD and control cats were unexpected in the current study.  Alpha-
enolase is considered a ubiquitous protein with the thymus and kidney containing greater 
amounts of protein than other organs. 4, 7  This conclusion was based on intense reactivity of 
rabbit α-enolase antiserum.to rabbit thymic tissue extracts via an immunoblot assay. 7 In this 
aforementioned study rabbit polyclonal anti-α-enolase serum was applied to several tissue 
extracts.  The thymus in particular was extracted from rabbit while the others were rat and 
human derived.  Perhaps the markedly intense immunoreactivity was due to high primary 
antibody concentrations, nonspecific staining or cross reactivity rather than an optimized protein 
quantification in this tissue.  Based on the findings in the current study, the kidney has greater 
protein expression than that of the thymus or liver by immunohistochemistry utilizing a 
monoclonal, mouse antibody. 
  In conclusion, renal α-enolase is increased in glomeruli and decreased in injured tubules 
of CKD cats when compared to healthy controls.  The mechanism for alteration of protein 
expression could be the result of hypoxia, increased anaerobic metabolism; or tubulointerstitial 
injury.  Additional studies to further elucidate the role of α-enolase enzyme in the pathogenesis 
of feline CKD are needed such as quantifying α-enolase mRNA, localizing cellular expression as 
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CHAPTER 7:  CELLULAR LOCALIZATION OF RENAL ALPHA-ENOLASE 
7.1 Chapter Summary 
Alpha-enolase is a ubiquitous glycolytic enzyme that is alternatively expressed on the plasma 
membrane where it can be targeted by autoantibodies in sera of patients with autoimmune 
diseases involving the kidney.  Anti-α-enolase antibodies can be induced experimentally in cats 
with prophylactic viral vaccines and occur naturally in cats with chronic kidney disease (CKD).  
The purpose of this study was to evaluate the cellular location of α-enolase in feline renal tissue 
homogenates.  A total of 29 CKD cats at various IRIS stages and 2 healthy controls were 
included in this study.  Renal tissue homogenates were fractionated and α-enolase protein was 
identified by western blot immunoassay.  Twenty-eight cats with CKD and both control cats had 
cytosolic α-enolase protein while only 16 CKD cats and a single control cat had membranous 
protein expression.  The number of cats with membranous α-enolase was significantly greater in 
later stages of kidney disease (p=0.006).  Eluted immunoglobulin from both azotemic and non-
azotemic cats bound endogenous cytosolic and membrane proteins at the approximate molecular 
weight as α-enolase.   
7.2 Introduction 
Autoimmune diseases occur due to the production of an adaptive immune response to self-
antigen.1  Specific T lymphocytes that recognize self-antigen are capable of causing tissue 
damage directly or indirectly by antigen presentation and subsequent antibody production by B 
lymphocytes.1  Frequently highly conserved intracellular enzymes are the target of 
autoantibodies in autoimmune diseases.2  The loss of self-tolerance is often spontaneous or 
idiopathic; however there is evidence that autoimmunity can be triggered by infectious agents via 
134 
 
molecular mimicry.1, 3  Regardless of the inciting cause, there is dysregulation of the immune 
response resulting in systemic or tissue specific injury by cellular or humoral defenses. 
Alpha-enolase is frequently reported as the target for autoantibodies in a myriad of 
diseases.3-5  Specifically, glomerular podocyte α-enolase has been identified as a target for 
autoantibodies by in vivo co-localization in human membranous glomerulonephritis and lupus 
nephritis biopsies.6, 7  Renal injury results from immune complex deposition, activation of 
complement and recruitment of inflammatory cells.8  In cats, interstitial nephritis has been 
documented to occur in association with the presence of experimentally induced anti-α-enolase 
antibodies.9, 10  Antibodies were induced by repeated administration of vaccines containing 
cellular contaminants as well as cell line lysates.9  Furthermore, azotemic client owned cats with 
known  FVRCP vaccine histories were more likely to have α-enolase antibodies than non-
azotemic cats.11    
Alpha-enolase is a ubiquitous glycolytic enzyme with highest concentrations in the 
thymus and kidney.12, 13  However, its function and location do not appear to be restricted to the 
cytoplasm to participate in glycolytic metabolism. In addition to catalyzing the conversion of 2-
phosphoglycerate to phosphoenolpyruvate, α-enolase can be expressed on the plasma membrane 
as a plasminogen receptor or act as a marker of hypoxia and heat stress.13-17  As a membrane 
bound protein it can also act as a target for autoantibodies.2  Shifting of enzyme expression to the 
plasma membrane may provide clues to possible pathogenesis of disease, such as its role in 
hypoxic stress or inflammation, and is in part the aim of this particular study.  In addition to 




7.3 Material and Methods 
7.3.1 Samples 
Cats with CKD presenting to Colorado State University Diagnostic Medical Center for necropsy 
and available serum from 2012 to 2014 were used for this study.  Samples were collected from 
any residual serum that remained after ante mortem routine biochemistry, at the owner’s 
permission.  Samples were stored at -20oC until assays could be run in batches.  Renal cortical 
tissue was taken at the time of necropsy, stored in RNAlater preservative, and frozen at -80oC.  
Similarly, tissues and serum from two healthy, non-azotemic, laboratory reared cats were used as 
controls.  Acquisition of tissues and serum was approved by Colorado State University’s 
Institutional Animal Care and Use Committee (IACUC).   Additional serum from non-azotemic, 
aged cats (>10 years old) from a previous study that were screened for α-enolase antibodies by 
western blot immunoassay were included for affinity chromatography assays.11 
7.3.2 Subcellular fractionation 
Renal cortical tissue was weighed (20mg), minced, rinsed in cold PBS, and disrupted by a hand 
held tissue homogenizer (Omni International, Inc).  Subcellular fractionation of membrane and 
cytosolic compartments was achieved using Qproteome Cell Compartment Kit (Qiagen) 
according to the manufacturer’s protocol.  Briefly, extraction buffer was added to homogenized 
tissue to disrupt the plasma membrane.  After centrifugation at 4000 rcf for 10 minutes at 4oC, 
the supernatant which contained cytosolic proteins was separated from the pellet.  The pellet 
which contained the plasma membrane and organelles was resuspended in a separate extraction 
buffer, incubated and centrifuged at 6000 rcf for 10 minutes at 4oC.  This supernatant contained 
plasma membranes proteins.  Cellular fractions were then desalted with acetone precipitation and 
resuspended with 0.5% Tween 20 in PBS (0.5% PBST).  Protein concentrations were determined 
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by the Pierce BCA Protein Assay Kit (Thermo Scientific).  Five micrograms of protein from 
each fraction was mixed with lithium dodecyl sodium (LDS) sample buffer, reducing agent, 
denatured and loaded on a precast 10% Bis-Tris mini gel along with a molecular weight standard 
(Thermo Scientific). Gels were electrophoresed in 3-(N-Morpholino)-propanesulfonic acid 
running buffer at 200V for 50 minutes.  Proteins were then transferred to a polyvinylidene 
difluorure (PVDF) membrane in transfer buffer with 20% methanol in a XCell II Blot Module 
(NuPage, Intitrogen, Carlsbad) at 25V for 90 minutes. 
 Membranes were blocked with 5% nonfat dry milk in PBS with 0.2% Tween 20 (0.2% 
PBST; Fisher Scientific) and then incubated with a primary mouse monoclonal anti-alpha-
enolase antibody (2.5μg/mL) overnight at 4oC (Abnova Taiwan Corp.).  Monoclonal mouse anti-
Na-K-ATPase (0.05μg/mL) and anti-GAPDH (Glyceraldehyde-3-phosphate-dehydrogenase, 
1:1000) blocked with 3% milk in PBS were optimized and used for confirmation of plasma 
membrane and cytosolic compartments, respectively (Millipore).  All membranes were washed 
with 5% nonfat dry milk in PBS with 0.2% PBST and subsequently incubated in goat-anti-mouse 
IgG (heavy and light chain) secondary antibody conjugated to horseradish peroxidase at room 
temperature for 1 hour (Abnova Taiwan Corp.).  Protein bands were visualized by colorimetric 
horseradish peroxidase (HRP) detection with 3, 3'-diaminobenzidine in 10% hydrogen peroxide 
buffer and analyzed by Quantity One (Bio-Rad) software.  Prevalence of α-enolase protein bands 
in subcellular fractions were compared between IRIS stages by chi-square analysis on GraphPad 
Prism version 5.00 for Windows (GraphPad Software, San Diego California USA, 




7.3.3 Affinity chromatography 
Serum samples from each of the following groups were pooled for a total final volume of 250-
300 μL and utilized for affinity chromatography assay:  CKD and aged, non-azotemic cats that 
were positive and negative for α-enolase antibody by western blot immunoblot.  Immunoglobulin 
G was purified with a commercially available antibody purification kit (Thermo Scientific) 
according to the manufacturer’s protocol as previously described.18-20  Briefly, serum was 
incubated with a Protein A agarose column in order to elute immunoglobulin G.  Gel 
electrophoresis and western blot membranes were prepared as previously described with 
recombinant α-enolase, cytosolic, and membrane fractions and stored at -20oC.  Membranes were 
thawed, rinsed with methanol and then with distilled water before blocked with TNTP + 10% 
milk at room temperature on a rocker for one hour.  Immunoglobulin concentration was 
optimized at 15μg in 10mL of TNTP + 10% milk (1.5μg/mL).  Membranes were incubated at 
4oC overnight with gentle rocking then washed with PBS-Tween 80 three times for 5 minutes.  
Secondary goat-anti-cat antibody was diluted 1:25 with 20mL of TNTP+milk.  Membranes were 
incubated with secondary antibody in the dark for 1 hour with gentle rocking at room 
temperature and rinsed with PBS-Tween 80.  Protein bands were visualized by colorimetric 
horseradish peroxidase (HRP) detection with 3, 3'-diaminobenzidine in 10% hydrogen peroxide 
buffer and analyzed by Quantity One (Bio-Rad) software. 
7.4 Results 
7.4.1 Subcellular fractionation 
Optimal concentrations of primary and secondary antibody were determined.  Serial dilutions of 
primary Na-K-ATPase antibody at 0.1 μg/mL, 0.05μg/mL, and 0.075 μg/mL were evaluated by 
western blot immunoassay with protein from membrane fractions.  Similarly, dilutions of 1:250, 
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1:500, and 1:1000 for GAPDH were evaluated by western blot immunoassay with protein from 
cytosolic fractions.  For each antibody, serial dilutions of secondary goat anti-mouse antibody at 
1:2000, 1:3000, and 1:5000 were employed. Optimal concentration for Na-K-ATPase was 0.05 
μg/mL while GAPDH antibody was optimal at 1:1000 both at 1:5000 dilution of secondary 
antibody.  Homogenized fractions required addition of detergent (0.5% PBS-Tween 20) to 
solubilize the protein pellet after acetone precipitation which reduced the appearance of multiple 
bands in the final immunoblot. 
Subcellular fractionation of renal cortical tissue from all CKD cats and 2 non-azotemic, 
healthy cats was achieved by the aid of a commercially available kit (Qiagen).  Cytosolic and 
membrane fractions were confirmed by the presence of positive bands at the appropriate 
molecular weight (MW) for GAPDH and Na-K-ATPase in respective fractions (Figure 7.1).  A 
prominent protein band was present in the cytosolic fraction at an approximate molecular weight 
of 62.3 kDa (range 60.2-63.5 kDa) that bound α-enolase monoclonal antibody in all but a single 
CKD cat (CKD 28/29, controls 2/2 Figure 7.2).  Sixteen CKD cats and a single control cat had a 
faint band at a similar molecular weight in the membrane fractions (mean 64.1 kDa, range 62.8-
65.2 kDa, Figure 7.3).  The single CKD cat that did not have detectable cytosolic α-enolase 
protein was negative in the membrane fraction as well.  Of the CKD cats, 8/9 Stage II cats had 
cytosolic protein and only 1/9 had α-enolase in the membrane fraction. All Stage III cats (8/8) 
had cytosolic α-enolase while 6/8 had protein in the membrane fraction.  Similarly all Stage IV 
cats (12/12) had cytosolic and 9/12 had membrane protein.  Cats in higher stages (i.e. Stages III 
and IV) of CKD were more likely to have α-enolase in the membrane fraction (p=0.006, Figure 
7.4).  Additional bands were present at approximately 182.7, 79.2, 76.1, 70.9, and 53.4 kDa in 
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the cytosolic fractions.  In the membrane fractions additional bands were present at 





Figure 7.1 Western blots of renal cortical cytosolic (Lane 1 and 3) and membrane (Lane 2 
and 4) fractions.  Lanes 1 and 2 GAPDH, Lanes 3 and 4 Na-K-ATPase.   








Figure 7.2 Cytosolic fractions from CKD cats with a common, dominant band at a mean 
molecular weight of 62.3 kDa.  Lane 1, blocking buffer (negative); Lane 2, recombinant α-














Figure 7.3 Membrane fractions from CKD cats with a common, dominant band at a 
mean molecular weight of 64.1 kDa.  Lane 1, blocking buffer (negative); Lane 2, 




Figure 7.4 Prevalence of CKD cats with membranous expression of α-enolase by IRIS 
stage expressed as a percentage of the group.  Expression was significantly more 
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7.4.2 Affinity chromatography 
Serum with and without α-enolase antibodies, confirmed by western blot immunoassay, from 
both CKD and aged, non-azotemic cats were used for this assay.  Immunoglobulin G was 
extracted from serum by affinity chromatography as described.  Immunoglobulin was quantitated 
and applied to western blots of renal cortical fractions at various dilutions (1.5 μg/mL, 7.5 μg/mL 
and 15.0 μg /mL).  Optimal concentration of IgG was determined to be 1.5 μg /ml. Immunoblots 
containing recombinant α-enolase, feline renal cytosolic and membrane proteins were incubated 
separately with IgG from aforementioned groups.  Immunodominant bands were similar between 
groups (Figure 7.5).  Recombinant enolase bands appeared at 54.3 kDa which was less than the 
theoretical MW of 73.5 kDa.  Dominant cytosolic protein bands were present at 51.7 kDa, 80.2 
kDa, and 43.7 kDa.  Membrane protein bands were present at 52.2 kDa and a single band at 30.6 
kDa in the membrane incubated with aged, non-azotemic feline serum that was negative by 



















Alpha-enolase has been characterized as an abundant, highly conserved cytosolic protein which 
is capable of acting as a plasminogen receptor on the cell membrane or up regulated in response 
to metabolic stress such as hypoxia.17 However, knowledge of protein expression and its role in 
disease states is mostly restricted to human and rodent models.  The purpose of this study was to 
characterize cellular expression of α-enolase in the cat kidney both in health and in CKD.  In 
addition, to complement previous serologic studies we were able to demonstrate that 
immunoglobulin present in cat sera was capable of binding to endogenous feline renal protein in 
vitro. 
Figure 7.5 Western blot of feline renal subcellular fractions incubated with 1.5 μg/mL 
of IgG from CKD cats (Lanes 2-7) and aged, non-azotemic cats (Lanes 8-13) that 
were either positive (Lanes 5-7 and 11-13) or negative (Lanes 2-4 and 8-10) for α-
enolase antibody by western blot immunoblot.  Lane 1 blocking buffer (negative); 
Lanes  2,5, 8, and 11 recombinant α-enolase; Lanes  3,6, 9, and 12 cytosolic 
fractions; Lanes 4, 7,10, and 13 membrane fractions.  








Subcellular fractionation of renal cortical tissue from CKD cats revealed the presence of 
dominant protein band that bound α-enolase monoclonal antibody in a majority of study cats.  
This protein was present in cytosolic and lesser membrane fractions in 28 and 16 CKD cats, 
respectively. However, the identified protein was not at the expected molecular weight (MW) for 
α-enolase which should be approximately 47 kDa.  In general, discrepancies in the expected 
molecular weight of proteins separated by gel electrophoresis can be the result of post-
translational modifications such as nitration, carbonylation, and phosphorylation, alternative 
splicing, or intrinsic factors such as protein charge or dimerization.21 Post-translational 
modifications of α-enolase have been documented in association with neoplasia, diabetic 
cardiomyopathy, aging, and Alzheimer’s disease.17  Oxidative stress can result in carbonylation 
and nitration of α-enolase which will modify the isoelectric point of the protein without change 
to the protein’s molecular weight.22, 23  It has been demonstrated that cats with CKD have 
increased markers of oxidative stress.24  This stress could potentially lead to protein 
modifications, altering α-enolase isoelectric point or molecular weight. In the present study, 
additional proteomics analyses to assess the presence of post-translational modifications in the 
kidney of CKD cats would be required to identify if such changes were present in feline renal α-
enolase.  Alternatively, protein bands at higher molecular weight could be the result of sample 
viscosity.  While optimizing the subcellular fractionation for gel electrophoresis and western blot 
immunoassay samples were eventually solubilized in 0.5% PBS-Tween 20 which resulted in a 
moderately to markedly viscous sample.   It is possible that the sample viscosity inhibited the 
electrophoretic mobility to some extent resulting in a slightly increased molecular weight by gel 
electrophoresis.25, 26  Additionally, the positive control--recombinant α-enolase--was not at the 
exact expected MW of 73.5 kDa but less at approximately 54.3 kDa in the affinity 
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chromatography western blots.  In this assay, the reduction in weight could be the consequence 
of loss of the GST tag (26 kDa) from the recombinant protein.  
Extraction of immunoglobulin by affinity chromatography revealed positive bands in 
samples that had previously tested negative for anti-α-enolase antibodies by western blot 
immunoassay.  A potential explanation for this could be that there was a soluble substance 
interfering with the immunoglobulin in the serum of cats with negative western blot 
immunoassays.  Or perhaps α-enolase antibody was less concentrated in these cats sera which 
brought about a false negative result by western blot immunoassay.   
In conclusion, this study has shown that α-enolase is predominantly expressed within the 
cytosol of cats with and without chronic kidney disease.  As the stage of CKD progresses (i.e. 
from Stage II to IV) membranous expression of α-enolase occurs more frequently.  Although a 
mechanism for the shift to membranous α-enolase expression has not been defined the data 
gathered in this study suggests that a relationship, either cause or effect, between the severity of 
CKD and a shift in cellular localization exists.2  Alpha-enolase can function as a plasminogen 
receptor, the site for conversion of plasminogen to plasmin in the fibrinolysis pathway, when 
expressed on cell membranes.27  Impaired fibrin clearance due to blocking of plasminogen 
receptors by anti-α-enolase antibodies leading to increased inflammation has been proposed.2, 27 
Further work to define the functional role of membranous α-enolase in cats with CKD, such as a 
plasminogen receptor, is needed. Furthermore, determining if there is an association between the 
presence and severity of renal inflammation and membranous α-enolase expression in cats with 
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CHAPTER 8: CONCLUDING REMARKS 
8.1 Significance of Work 
It has been well established that feline chronic kidney disease (CKD) affects many cats and can 
have significant consequences.  There are many gaps in our current knowledge as to the leading 
cause(s) and pathogenesis of this syndrome.   The ultimate goal for this dissertation was to 
elevate our knowledge in an attempt to bridge some of these gaps.  In Chapter 3, we described 
various patterns and characteristics of renal lesions at the different stages of CKD.  Unique 
lesions and specific patterns will hopefully guide future studies in potential etiologies and 
therapies.  In Chapter 4 we characterized gastric lesions in cats with CKD.  Our findings will 
undoubtedly impact current therapeutic regimens.  For the second part of this dissertation we 
explored the role of α-enolase and autoantibodies in feline CKD.  Chapter 5 demonstrated the 
presence of anti-α-enolase antibodies in the serum of cats with CKD that were capable of binding 
to endogenous renal proteins.  Chapter 6 characterized the expression of α-enolase protein in 
healthy and CKD cats while Chapter 7 went a step further and described the subcellular protein 
expression.  The data generated from the second portion of this project are in large descriptive 
but have some interesting potential etiopathogenic implications for feline CKD.   
8.2 Specific Aim 1 (Chapter 3: Histopathology of CKD IRIS stages) 
This chapter documented differences in histologic lesions and patterns among the four stages of 
CKD. The severity of tubular degeneration, interstitial inflammation, fibrosis, and 
glomerulosclerosis was significantly greater in later stages of CKD compared to early stages of 
disease, although glomerulosclerosis was the only variable that increased significantly with each 
disease stage. This latter finding is unique to this study as glomerulosclerosis was mild and not 
different among stages in a previous study of cats with CKD.1 Sclerosis, or hardening of the 
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glomerulus can occur for a variety of reasons.  Maladaptive hyperfiltration and ischemia can 
result in glomerulosclerosis with the latter considered in the aforementioned study to be the more 
probable pathogenesis based on pattern of glomeruli histopathologically.1, 2  This is of 
particularly interest in conjunction with the vascular findings in this study.  Fibrointimal 
hyperplasia, a thickening of the vascular intima, was found in 56.5% of CKD cats and could 
have potential hemodynamic consequences that warrant further investigation.    Proteinuria was 
associated with increased severity of tubular degeneration, inflammation, fibrosis, tubular 
epithelial single cell necrosis and decreased normal parenchyma. These findings will help 
pinpoint therapeutic targets and the stage of disease at which they should be initiated, in addition 
to potential implications as to the pathogenesis of CKD in the cat.    
8.3 Specific Aim 2 (Chapter 4: Uremic gastropathy) 
Uremic gastritis, consisting of necrosis, hemorrhage, and ulceration has been documented in 
humans with renal failure.3  While dogs appear to be less affected by necrosis and mucosal 
ulceration, no histologic assessment of gastric pathology in cats with CKD has been performed.4, 
5   The aim of this chapter was to evaluate the type and prevalence of histopathologic lesions in 
the stomach of cats with CKD, and to determine whether the degree of azotemia, calcium-
phosphorus products and serum gastrin concentrations correlated with gastric pathology.  
The most significant gastric lesions in CKD cats were fibrosis and mineralization. Gastric 
ulceration, hemorrhage, edema, and vascular injury, were not observed in cats with CKD.  Only 
cats with moderate and severe azotemia had gastric mineralization. Calcium-phosphorus product 
(CPP) was correlated to disease severity.  Severely azotemic CKD cats had significantly greater 
CPP when compared to non-azotemic controls, and to mildly and moderately azotemic cats. 
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Gastrin concentrations were significantly greater in CKD cats when compared to non-azotemic 
controls but elevated concentrations were not associated with gastric ulceration. 
 These data suggest that the therapeutic administration of gastric protectants such as 
sucralfate may not be justified in cats with CKD.  Medical management of gastrointestinal 
symptoms with anti-emetic and anti-nausea drugs may be more appropriate in ameliorating 
clinical symptoms attributable to uremia. Gastric mineralization, likely the consequence of 
metastatic mineralization, suggests that interventions to reduce hyperphosphatemia and renal 
secondary hyperparathyroidism are indicated.  Lastly, the exact role of hypergastrinemia in 
contributing to gastric hyperacidity and/or gastric lesions in cats with CKD is still unclear. 
Further studies to determine gastric acidity and normal gastric pathology in cats are needed in 
order to close this gap in our understanding of the etiopathogenesis of hypergastrinemia in feline 
uremia. 
8.4 Specific Aim 3 (Chapter 5: Alpha-enolase antibodies in serum and endogenous renal 
targets) 
Systemic lupus erythematosus (SLE) is an autoimmune disease in which patients have 
autoantibodies that target a variety of cellular components.  Of interest, anti-α-enolase antibodies 
have been associated with active nephritis and recovery in SLE patients.6-8  Anti-α-enolase 
antibodies can be induced experimentally in cats and inducible autoantibodies have been 
associated with interstitial nephritis.9, 10  In this chapter, the goal was to determine if cats with 
naturally occurring CKD at various stages and with variable vaccine exposure had significant 
serum anti-α-enolase antibodies.  In addition, it was determined that endogenous renal α-enolase 
was a target for circulating autoantibodies. 
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Cats with CKD had significantly higher levels of serum anti-α-enolase antibodies than 
healthy, non-azotemic control cats.  Alpha-enolase antibodies increased with each stage (Stage 
II-IV); however the difference between each stage was not statistically significant.  Lack of 
statistical significance may be a consequence of a small sample size for each stage. If 
autoantibodies to α-enolase do indeed increase with stage then there are potential diagnostic or 
pathogenic implications of these antibodies.  Autoantibodies can be produced in response to 
cellular injury for tissue repair.11, 12  Renal tubular injury in feline CKD, which includes 
degeneration and epithelial cell death, were described in Chapter 3.  These histologic variables of 
tubular injury increase with stage and thus could potentially be the cause for an increase in 
autoantibodies. Alternatively, autoantibodies induced by vaccination could be the cause for renal 
injury.  Vaccination status could only be confirmed in 9/29 CKD cats in this study and thus an 
association between vaccination exposure and antibody levels could not be determined.  Future 
studies should be concentrated on evaluating anti-α-enolase antibodies in cats with and without 
naturally occurring CKD with known vaccine histories.  Furthermore, correlation of antibody 
levels and histologic variables of renal injury in cats with CKD are warranted to evaluate the 
potential pathogenicity of α-enolase antibodies.  
8.5 Specific Aim 4 (Chapter 6: Renal α-enolase protein expression) 
Alpha-enolase is  best known as a cytoplasmic, glycolytic enzyme in most cell types.13, 14  
However, It is not restricted to its glycolytic role in the cytosol.  It can be up regulated in the cell 
in response to physiologic stress, expressed on the cell membrane as a plasminogen  receptor, C-
peptide receptor, or marker of apoptosis to name a few.15-20  In addition protein expression in 
kidneys of patients with active nephritis is differentially expressed and is targeted by 
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autoantibodies.6-8  Differences in protein expression could give clues to the metabolic state of 
tissues or pathogenesis of a particular disease. 
 In this chapter, an immunohistochemical assay utilizing a monoclonal mouse antibody 
was optimized and validated in feline tissues to assess protein expression in health and CKD.  
Renal α-enolase was primarily expressed in renal cortical tubules in healthy cats with absent to 
minimal expression in glomeruli.  In contrast, tubular expression was less in injured tubules 
while glomerular expression was increased in CKD cats compared to healthy controls.  Alpha-
enolase expression in the glomeruli of CKD cats was present in the cytoplasm of mesangial cells, 
visceral and parietal epithelium.  Hepatic protein expression was similar between healthy and 
CKD cats which indicates that there is not likely a systemic down regulation of α-enolase 
enzyme in cats with CKD.  Implications of the differential expression may be an indicator of the 
metabolic state of the kidney.  Perhaps there is increased expression in glomeruli and a few 
remaining morphologic normal tubules as a response to local tissue hypoxia or increased 
metabolic demand on remaining, functioning nephrons.  Studies have shown that whilst renal 
tubular epithelial cells did not up regulate enolase in response to hypoxic conditions the in vitro 
conditions were extreme.20, 21  It is more likely that local tissue oxygen tension could be reduced, 
due to loss of peritubular capillaries, increased interstitial fibrosis and inflammation, but not 
absent and it would be of interest to explore what the metabolic response of tubular cells and 
glomerular epithelial cells are under these conditions.    This may include investigating 
expression of hypoxic markers like hypoxia inducible factor (HIF-1α) or vascular endothelial 
growth factor (VEGF-A) in correlation with α-enolase expression in cats with CKD.  Lastly, 




8.6 Specific Aim 5 (Chapter 7: Cellular localization of α-enolase) 
To complement the previous chapter which addressed α-enolase protein expression in cats with 
CKD, this aim expanded our understanding of protein expression to the subcellular level.  Alpha-
enolase has multiple functions as a membranous protein.  A few include plasminogen receptor, 
apoptotic marker, and target for autoantibodies.6, 7, 16-18, 22-24   Localization of protein in cats with 
CKD has possible etiopathogenic implications.  
In this chapter, kidney homogenate was fractionated into cytosolic and membranous 
fractions and α-enolase protein was identified by immunoblot.  Protein expression was 
predominately in the cytosolic fractions as would be expected; however in over half of CKD cats 
had membranous α-enolase, albeit subjectively weaker.  Membranous expression in cats with 
CKD could indicate that in this disease there is a functional shift for this protein.  Perhaps in 
these cells, α-enolase is acting as a plasminogen receptor or externalized as a result of apoptosis.  
In the case of the latter it would be plausible that in cats with CKD that due to ongoing tissue 
injury that there is some degree of apoptosis.  In addition, we were able to show that 
immunoglobulin in cat sera is capable of binding renal endogenous proteins in both cytosolic and 
membranous fractions.  It is debatable if this binding translates in vivo or if autoantibodies are 
indeed pathogenic as there is little evidence that feline CKD is an immune-complex mediated 
disease.1, 9, 11  Additional studies such as that done by Bruschi et al co-localizing protein and 
antibodies in tissues would be of interest.6, 7 Lastly, evaluating a subset of aged matched cats 
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